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1What the Clinician Should Know
Chapter One
In 1989, the Centers for Disease Control and Prevention (CDC) announced thegoal of eliminating tuberculosis (TB) from the United States by the year2010. The Strategic Plan for the Elimination of Tuberculosis in the United States was
published at that time, and reassessed in 1999, to identify the actions necessary to achieve
elimination. In 1992, a special federal task force was convened to address the problem of
increasing case rates and outbreaks of drug-resistant TB. This task force developed the
National Action Plan to Combat Multidrug-Resistant Tuberculosis, which enhanced the
original Strategic Plan. Both plans stress the need to increase clinical knowledge about TB
disease and infection.
Since 1993, TB case rates have been declining, suggesting that the nation is recovering
from the resurgence of TB that occurred in the mid-1980s, and is back on track toward TB
elimination. While the decrease in TB case rates is encouraging, there are several areas of
concern that will require expanded efforts:
• TB cases continue to be reported in every state
• Drug-resistant TB cases continue to be reported
in almost every state
• An estimated 10 to 15 million persons in the U.S.
are infected with Mycobacterium tuberculosis.
Without intervention, about 10% of these persons
will develop TB disease at some point in life.
An update on TB for clinicians is critical today. The oc-
currences of several outbreaks of multidrug-resistant TB
have pointed to the need for new treatment regimens and
the more effective use of current ones. New methods of
diagnosis have been introduced, and guidelines for pa-
tient management and public health practice have been
revised.
This curriculum was designed to present basic information about TB for health care profes-
sionals. It is intended for use as a reference manual for clinicians caring for persons with or
at high risk for TB disease or infection. In addition, it was designed to be useful in develop-
ing educational programs. It is not meant to provide detailed answers to all public health
or clinical questions about TB, nor is it meant as a substitute for any specific guidelines.
Information contained in this document is current as of April 2000.
Introduction
Areas of Concern
➤ TB cases continue to be reported in every state
➤ Drug-resistant cases reported in almost every
state
➤ Estimated 10-15 million persons in U.S. infected
with M. tuberculosis
➤ Without intervention, about 10% will develop
TB disease at some point in life
SLIDE 4
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In preparing this document, our aim was to meet the following goals:
• To increase clinicians’ knowledge of the current TB trends.
• To assist clinicians with identifying those at highest risk for TB infection and disease.
• To increase clinicians’ index of suspicion for TB in high-risk patients.
• To increase clinicians’ use of treatment for high-risk persons with latent TB infection.
• To increase clinicians’ knowledge about appropriate and effective treatment regimens.
• To increase clinicians’ use of directly observed therapy (DOT) and other adherence-
promoting methods.
• To assist clinicians with identifying appropriate measures to prevent TB transmission
in health care settings.
• To assist clinicians with identifying resources for patients with TB.
This document was originally developed by the 1989 National Tuberculsosi Training Initia-
tive 1 cosponsored by the American Thoracic Society and CDC. Because the guidelines for
treating and controlling TB continue to evolve, it has been necessary to periodically revise
this curriculum. The current document is the fourth edition of the Core Curriculum on
Tuberculosis.
Endnotes
1. Reichman L. The National Tuberculosis Training Initiative. Ann Intern Med 1989;111:197-
198.
Continuing medical education (CME) credits, continuing nursing education (CNE)
credits, and continuing education unit (CEU) credits are available for this publica-
tion. See page 127 for information on how to obtain continuing education credits.
This curriculum is based on the following documents published by the American Thoracic
Society, the Advisory Council for the Elimination of Tuberculosis, the American Academy
of Pediatrics, and the CDC. We recognize that documents prepared by other professional
organizations may contain minor differences in recommendations. Each reference is also
listed in the appropriate chapter.
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• The CDC Fax Information Service at (888) CDC-FAXX (232-3299)
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Summary. TB is a communicable disease caused by Mycobacterium tuberculosis,
or the tubercle bacillus. It is spread primarily by tiny airborne particles (droplet
nuclei) expelled by a person who has infectious TB. If another person inhales air
containing these droplet nuclei, transmission may occur. Some bacilli reach the
alveoli, where they are ingested by macrophages. Infection begins with the multi-
plication of tubercle bacilli within these alveolar macrophages. Some of the bacilli
spread through the bloodstream when the macrophages die; however, the immune
system response usually contains the bacilli and prevents the development of dis-
ease. Persons who are infected but who do not have TB disease are asymptomatic
and not infectious; such persons usually have a positive reaction to the tuberculin
skin test. About 10% of infected persons will develop TB disease at some time in
life, but the risk is considerably higher for persons who are immunosuppressed,
especially those with HIV infection. Although the majority of TB cases are pulmo-
nary, TB can occur in almost any anatomical site or as disseminated disease.
Objectives
After working through this chapter, you will be able to
• Describe how TB is spread;
• List at least 10 conditions that increase the risk that TB infection will progress to
TB disease;
• Define primary and secondary drug resistance;
• Describe the classification system for TB.
In the United States, the vast majority of TB cases are caused by Mycobacterium tuberculo-
sis, sometimes referred to as the tubercle bacillus. M. tuberculosis and three very closely
related mycobacterial species (M. bovis, M. africanum, and M. microti) can cause tubercu-
lous disease, and they compose what is known as the M. tuberculosis complex. M. bovis and
M. africanum are very rare causes of disease in the United States; M. microti does not cause
disease in humans. Mycobacteria other than those comprising the M. tuberculosis complex
are called nontuberculous mycobacteria. Nontuberculous mycobacteria may cause pulmo-
nary disease resembling TB.1
Chapter Two
Transmission and Pathogenesis
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Transmission
TB is spread from person to person through the air. When a
person with pulmonary or laryngeal TB coughs, sneezes,
speaks, or sings, droplet nuclei containing M. tuberculosis
are expelled into the air. Depending on the environment,
these tiny particles (1-5 microns in diameter) can remain
suspended in the air for several hours.
If another person inhales air containing droplet nuclei, trans-
mission may occur. The probability that TB will be trans-
mitted depends on four factors: (1) the infectiousness of
the person with TB (the number of organisms expelled into
the air), (2) the environment in which exposure occurred,
(3) the duration of exposure, and (4) the virulence of the
organism. (See Infection Control in Health Care Settings,
p. 87, for more information on infectiousness.)
The best way to stop transmission is to isolate patients with
infectious TB immediately and start effective TB therapy.
Infectiousness declines rapidly after adequate therapy is
started, as long as the patient adheres to the prescribed
regimen.
Persons at the highest risk of becoming infected with M. tu-
berculosis are close contacts — persons who had prolonged,
frequent, or intense contact with a person with infectious
TB. Close contacts may be family members, roommates,
friends, coworkers, or others. Data collected by CDC since
1987 show that infection rates have been relatively stable,
ranging from 21% to 23% for the contacts of infectious TB
patients.2
Among contacts of persons with drug-resistant TB, infection rates seem to be similar. How-
ever, because they may have a poor response to treatment, persons with drug-resistant dis-
ease are often infectious for longer periods and therefore have the potential to infect more
contacts. HIV-positive persons with TB disease are not considered more infectious than
HIV-negative persons with TB disease.
Extrapulmonary TB is rarely contagious (except for laryngeal TB); however, transmission
from extrapulmonary sites has been reported during aerosol-producing procedures, such as
autopsies and tissue irrigation. 3,4,5
Transmission of M. tuberculosis
➤ Spread by droplet nuclei
➤ Expelled when person with infectious TB coughs,
sneezes, speaks, or sings
➤ Close contacts at highest risk of becoming
infected
➤ Transmission occurs from person with infectious
TB disease (not latent TB infection)
SLIDE 6
Probability TB Will Be Transmitted
➤ Infectiousness of person with TB
➤ Environment in which exposure occurred
➤ Duration of exposure
➤ Virulence of the organism
SLIDE 7
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Pathogenesis
When droplet nuclei are inhaled, most of the larger particles become lodged in the upper
respiratory tract, where infection is unlikely to develop. However, smaller droplet nuclei
containing the tubercle bacilli may reach the alveoli, where infection begins.
The tubercle bacilli that reach the alveoli are ingested by alveolar macrophages; the major-
ity of these bacilli are destroyed or inhibited. A small number multiply intracellularly and
are released when the macrophages die. These bacilli can spread through the lymphatic
channels to regional lymph nodes and then through the bloodstream to more distant tissues
and organs, including areas in which TB disease is most likely to develop: the apices of the
lungs, the kidneys, the brain, and bone. Extracellular bacilli attract macrophages from the
bloodstream. The immune response kills most of the bacilli, leading to the formation of a
granuloma. At this point the person has TB infection, which can be detected by using the
tuberculin skin test. It may take 2-10 weeks for the infected person to develop a positive
reaction to the tuberculin skin test. Immune responses soon develop to kill the bacilli. Within
2 to 10 weeks after infection, the immune system is usually able to halt the multiplication of
the tubercle bacilli, preventing further spread.
Persons who are infected with M. tuberculosis, but who do not have TB disease cannot
spread the infection to other people. TB infection in a person who does not have TB disease
is not considered a case of TB and is often referred to as latent TB infection (LTBI).
In some people, TB bacilli overcome the defenses of the immune system and begin to mul-
tiply, resulting in the progression from TB infection to TB disease. This process may occur
soon after or many years after infection. In the United States, unless they are treated, ap-
proximately 5% of persons who have been infected with M. tuberculosis will develop TB
disease in the first year or two after infection and another 5% will develop disease sometime
later in life. Recent infection (within the past 2 years) with M. tuberculosis is therefore an
important risk factor for progression to TB disease. In all, in approximately 10% of persons
with normal immune systems who are infected with M. tuberculosis, TB disease will de-
velop at some point.
Some medical conditions increase the risk that TB infec-
tion will progress to disease. Some studies suggest that the
risk may be approximately 3 times greater (as with diabe-
tes)6,7 to more than 100 times greater (as with HIV infec-
tion) 6, 7, 8 for persons who have these conditions than for
those who do not. HIV infection is the strongest known
risk factor for development of TB disease in persons with
LTBI. Compared with immunocompetent persons who are
infected with M. tuberculosis, infected persons who are
immunosuppressed are at considerably greater risk of de-
veloping TB disease. For example, studies suggest that the
risk of developing TB is 7% to 10% each year for persons
who are infected with both M. tuberculosis and HIV,8,9
whereas it is 10% over a lifetime for persons infected only
with M. tuberculosis.
Pathogenesis
➤ 10% of infected persons with normal immune
systems develop TB at some point in life
➤ HIV strongest risk factor for development of TB if
infected
➤ Risk of developing TB disease 7% to 10%
each year
➤ Certain medical conditions increase risk that TB
infection will progress to TB disease
SLIDE 8
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Conditions that increase the risk of progression to TB
disease include:
• HIV infection
• Substance abuse (especially drug injection)
• Recent infection with M. tuberculosis (within the
past 2 years)
• Chest radiograph findings suggestive of previous




• Prolonged corticosteroid therapy
• Other immunosuppressive therapy
• Cancer of the head and neck
• Hematologic and reticuloendothelial diseases
(e.g., leukemia and Hodgkin’s disease)
• End-stage renal disease
• Intestinal bypass or gastrectomy
• Chronic malabsorption syndromes
• Low body weight (10% or more below the ideal)
TB disease most commonly affects the lungs; 73% of TB
cases are exclusively pulmonary.10 Patients with pulmo-
nary TB usually have a cough and an abnormal chest
radiograph, and are likely to be infectious.
However, TB is a systemic disease and may also com-
monly occur in the following ways: as a pleural effusion;
in the central nervous, lymphatic, or genitourinary sys-
tems; in the bones and joints; or as disseminated disease
(miliary TB). More rarely, TB can occur in other body
sites; for example, the breast, skin, or peritoneum.
Extrapulmonary TB is more common in immunosup-
pressed persons and in young children; lymphatic TB and
miliary disease are particularly common in immunosup-
pressed persons. Extrapulmonary TB is often accompa-
nied by pulmonary TB.
SLIDE 11
Common Sites of TB Disease
➤ Lungs
➤ Pleura
➤ Central nervous system
➤ Lymphatic system
➤ Genitourinary systems
➤ Bones and joints
➤ Disseminated (miliary TB)
Conditions That Increase the Risk




➤ Chest radiograph findings suggestive of previous TB
➤ Diabetes mellitus
➤ Silicosis
➤ Prolonged corticosteriod therapy
➤ Other immunosuppressive therapy
SLIDE 9
SLIDE 10
Conditions That Increase the Risk
of Progression to TB Disease
(cont.)
➤ Cancer of the head and neck
➤ Hematologic and reticuloendothelial diseases
➤ End-stage renal disease
➤ Intestinal bypass or gastrectomy
➤ Chronic malabsorption syndromes
➤ Low body weight (10% or more below the ideal)
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Drug-Resistant Tuberculosis
Drug-resistant TB is transmitted in the same way as drug-
susceptible TB. The earlier outbreaks of multidrug-resis-
tant TB support the findings that drug-resistant TB is no
less infectious than drug-susceptible TB, although pro-
longed periods of infectiousness that often occur in pa-
tients with drug-resistant TB may facilitate transmission.
Drug resistance is divided into two types: primary resis-
tance and secondary (or acquired) resistance. Primary re-
sistance develops in persons who are initially infected with
resistant organisms. Secondary resistance, or acquired
resistance, develops during TB therapy, either because the
patient was treated with an inadequate regimen or because
the patient did not take the prescribed regimen appropriately.
Classification System
The current clinical classification system for TB is based on the pathogenesis of the disease
(see table 1). TB disease should be ruled in or out within 3 months. Therefore, a patient
should not have a class 5 classification for more than 3 months.
Health care providers should comply with state and local laws and regulations requiring the
reporting of TB. All persons with class 3 or class 5 TB should be reported promptly to the
state and local health department.
SLIDE 12
Drug-Resistant TB
➤ Drug-resistant TB transmitted same way as drug-
susceptible TB
➤ Drug resistance is divided into two types:
➤ Primary resistance develops in persons
initially infected with resistant organisms
➤ Secondary resistance (acquired resistance)
develops during TB therapy
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Table 1. Classification System for TB
 Class Type Description
     0 No TB exposure No history of exposure
Not infected Negative reaction to tuberculin skin test
     1 TB exposure History of exposure
No evidence of infection Negative reaction to tuberculin skin test
     2 TB infection Positive reaction to tuberculin skin test
No disease Negative bacteriologic studies (if done)
No clinical, bacteriological, or radiographic
evidence of active TB
     3 TB, clinically active M. tuberculosis cultured (if done)
Clinical, bacteriological, or radiographic
evidence of current disease
     4 TB History of episode(s) of TB
Not clinically active or
Abnormal but stable radiographic findings
Positive reaction to the tuberculin skin test
Negative bacteriologic studies (if done)
and
No clinical or radiographic evidence of current
disease
     5 TB suspected Diagnosis pending
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Study Questions
Answers to these questions can be found in the text.
1. How is TB spread?
2. After TB has been transmitted, how long does it take before TB infection can be
detected with a tuberculin skin test?
3. What conditions increase the risk that TB infection will progress to disease?
4. Describe the classification system for TB.
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Summary. After the introduction of anti-TB medication in the late 1940s, there
was hope that TB would soon be eradicated. There was a steady decline in the
incidence of TB in the United States from 1953 through 1984. However, from
1985 through 1992, the number of reported TB cases increased by 20%. Since
1993, the number of TB cases reported has again declined, and the nation has
recovered from the resurgence of TB that occurred in the mid-1980s. However,
the nation cannot let its guard down when the goal is TB control and prevention
and eventual elimination of TB as a public health threat. Although the overall
number of TB cases is decreasing, TB cases continue to be reported in every
state. During 1998, a total of 18,361 new cases (rate of 6.8 per 100,000 popula-
tion) of TB were reported to CDC from the 50 states and the District of Colum-
bia. Surveillance data have shown that TB in the United States affects racial/
ethnic minorities disproportionately. Resistance to anti-TB drugs among reported
TB cases in the United States remains a serious public health concern. An esti-
mated 10 to 15 million persons in this country are infected with M. tuberculosis.
TB disease may develop in these persons at some time in the future. Efforts to
control TB through the prompt identification and treatment of persons with in-
fectious TB can reduce the number of newly infected persons who are added to
this population. Some groups are at higher risk for TB than others. These groups
can be divided into two categories: persons at higher risk for exposure to or
infection with M. tuberculosis, and persons at higher risk of developing TB dis-
ease once infected with M. tuberculosis.
Objectives
After working through this chapter, you will be able to
• Describe how the number of TB cases reported in the United States has changed
recently;
• List the racial and ethnic groups that are disproportionately affected by TB.
Chapter Three
Epidemiology of TB in the United States
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Trends
After the introduction of anti-TB medication in the late
1940s, there was hope that TB would soon be eradicated.
There was a steady decrease in the incidence of TB in the
United States from 1953 through 1984 (figure 1). The
number of reported cases declined by an average of 5.6%
per year, from more than 84,000 cases in 1953 to 22,255
cases in 1984.1 However, after decades of steady decline
in TB, from 1985 through 1992 the number of reported
TB cases increased by 20%.2 The major factors contrib-
uting to this increase were
• A deterioration of the TB public health
infrastructure
• The HIV/AIDS epidemic
• Immigration from countries where TB is common
• Transmission of TB in congregate settings (e.g.,
health care facilities, correctional facilities, home-
less shelters)
Since 1993, the number of reported TB cases has again
declined; the nation has recovered from the resurgence
of TB that occurred in the mid-1980s, and is back on
track toward TB elimination. This decline has been pri-
marily attributed to increased efforts to strengthen TB
control programs that promptly identify persons with TB,
initiate appropriate treatment, and ensure the completion
of therapy.3
During 1998, a total of 18,361 cases (rate of 6.8 per
100,000 population) of TB were reported to CDC from
the 50 states and the District of Columbia, representing
an 8% decrease from 1997.1 This sixth annual consecu-
tive decline in the number of reported TB cases also marks
the lowest number and rate of reported TB cases since
national reporting began in 1953.
Although the overall number of TB cases is decreasing,
TB cases continue to be reported in every state. In 1998
seven states (California, Florida, Georgia, Illinois, New
Jersey, New York, and Texas) reported 60% of all TB
cases.1 Cases of TB remain concentrated in urban areas:
in 1998, nearly 40% of TB cases were reported from 64
major cities.1
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TB Morbidity Trends in the
United States
➤ From 1953 to 1984, reported cases decreased
by an average of 5.6% per year
➤ From 1985 to 1992, reported TB cases increased
by 20%
➤ Since 1993, reported TB cases have been
declining again
➤ 18,361 cases reported in 1998
Factors Contributing to the
Increase in TB Morbidity: 1985-1992
➤ Deterioration of the TB public health
infrastructure
➤ HIV/AIDS epidemic
➤ Immigration from countries where TB is common
➤ Transmission of TB in congregate settings
Factors Contributing to the
Decrease in TB Morbidity Since 1993
Increased efforts to strengthen TB control programs
that
➤ Promptly identify persons with TB
➤ Initiate appropriate treatment
➤ Ensure completion of therapy
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During 1992–1998, the overall decrease in TB cases reflected the substantial decline in
cases among U.S.-born persons in all age groups and a small increase in the number of
cases among foreign-born persons. Although the number of TB cases among foreign-born
persons increased 4% during this period,1 most of these foreign-born TB patients were
probably infected before arrival in the United States.4 The proportion of TB cases among
foreign-born persons has increased steadily since the mid-1980s and increased markedly
since 1992 (from 27% in 1992 to 42% in 1998) (figure 2).1 The TB case rate for foreign-
born persons has remained at least four to six times higher than that for U.S.-born persons.1
Surveillance data have shown that TB in the United States affects racial/ethnic minorities
disproportionately. Compared with non-Hispanic whites, Asians are almost 16 times more
likely to have TB; African Americans 8 times more likely; and Hispanics, Native Ameri-
cans, and Alaskan Natives 5 times more likely.1  However, it has been suggested that much
of the increased risk for TB, particularly among U.S.-born persons in these racial/ethnic
minorities, may be due to socioeconomic status.5
HIV-positive persons are at high risk for active TB disease after infection with M. tubercu-
losis. Because incomplete reporting has limited the analysis of national TB surveillance
data by HIV status, state health departments have compared TB and AIDS registries to help
estimate the proportion of reported TB cases with HIV coinfection. In the most recent reg-
istry comparison conducted by the 50 states and Puerto Rico, 14% of all TB cases reported
during 1993–1994 had a match in the AIDS registry; 27% of cases were in persons aged 25–
44 years.6  Both this study and recent TB surveillance data indicate that the impact of the
HIV/AIDS epidemic also differs by geographic location.1
Figure 1. Reported TB Cases in the United States, 1953–1998




































Multidrug-resistant TB (MDR TB), particularly among
HIV-positive persons, contributed to the resurgence of
TB in the late 1980s and early 1990s. Even now, resis-
tance to anti-TB drugs among reported TB cases in the
United States remains a serious public health concern.
Since CDC began monitoring anti-TB drug resistance
through the national TB surveillance system in 1993, lev-
els of isoniazid resistance have been relatively stable.1,7
Even among patients without a history of prior TB, resis-
tance to isoniazid was 4% or higher in 46 states and the
District of Columbia during 1993-1998.8 Overall, the
number and proportion of MDR TB cases has decreased.1,7
Nevertheless, 45 states and the District of Columbia re-
ported at least one MDR TB case during 1993-19988
(figure 3). The extent of drug resistance confirms the im-
portance of initial treatment regimens of four first-line drugs for most TB patients and the
use of drug susceptibility testing to guide optimal treatment of patients with culture-posi-
tive disease. All health departments must be prepared to deal with the challenge of MDR
TB, which includes the capacity to ensure that clinicians with expertise in the management
of MDR TB are always involved in the care of these patients.
Figure 2. Tuberculosis case rates by origin: United States, 1986–1998
Multidrug-Resistant TB (MDR TB)
Remains a Serious Public Health
Concern
➤ Resistance to INH ≥ 4% in 46 states and District
of Columbia (DC) during 1993-1998
➤ 45 states and DC reported at least one MDR TB
case during 1993-1998
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The decrease in TB cases and MDR TB is encouraging; however, the earlier resurgence of
TB taught a valuable lesson. The nation cannot let its guard down when the goal is TB
control and prevention, as well as eventual elimination of TB as a public health threat.
Every TB case is a potential outbreak, and maintaining strong TB control programs nation-
wide is essential in working toward this goal (See Community TB Control, p. 103). All
health departments must be prepared to promptly identify persons who have active TB
disease, to ensure that standards of care are met with respect to diagnosis and treatment
(including prompt initiation and completion of therapy), and to identify and appropriately
treat those who may have been infected through close contact with persons who have infec-
tious TB.
Risk Groups
The following persons are at higher risk for exposure to
or infection with M. tuberculosis:
• Close contacts of persons known or suspected to
have TB (i.e., those sharing the same household
or other enclosed environments)
• Foreign-born persons, including children, from
areas that have a high TB incidence or prevalence
(e.g., Asia, Africa, Latin America, Eastern Europe,
Russia)
• Residents and employees of high-risk congregate
settings (e.g., correctional institutions, nursing




Persons at Higher Risk for
Exposure to or Infection with TB
➤ Close contacts of person known or suspected to
have TB
➤ Foreign-born persons from areas where TB is
common
➤ Residents and employees of high-risk
congregate settings
➤ Health care workers (HCWs) who serve high-risk
clients
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homes, mental institutions, other long-term residential fa-
cilities, and shelters for the homeless)
• Health care workers who serve high-risk clients
• Some medically underserved, low-income
populations as defined locally
• High-risk racial or ethnic minority populations,
defined locally as having an increased preva-
lence of TB (e.g., Asians and Pacific Islanders,
Hispanics, African Americans, Native Ameri-
cans, migrant farm workers, or homeless per-
sons)
• Infants, children, and adolescents exposed to
adults in high-risk categories
• Persons who inject illicit drugs; any other lo-
cally identified high-risk substance users (e.g.,
crack cocaine users)
Persons who are at higher risk of developing TB
disease once infected with M. tuberculosis include
• Persons with HIV infection
• Persons who were recently infected with
M. tuberculosis (within the past 2 years), particu-
larly infants and very young children
• Persons who have medical conditions known
to increase the risk for disease if infection occurs,
e.g., diabetes, end-stage renal disease (see
Transmission and Pathogenesis, p. 8)
• Persons who inject illicit drugs; other groups
of high-risk substance users (e.g., crack cocaine
users)
• Persons with a history of inadequately treated
TB
An estimated 10 to 15 million persons in this country are infected with M. tuberculosis. TB
disease may develop in these persons at some time in the future. Efforts to control TB
through the prompt identification and treatment of persons with infectious TB can reduce
the number of newly infected persons who are added to this population. Targeted testing of
high-risk populations for TB infection and providing treatment for infection are crucial to
achieving the nation’s goal of eliminating TB. However, testing should not be given prefer-
ence over higher priority TB prevention and control activities, such as identifying and com-
pletely treating all persons who have active TB, and conducting prompt contact investiga-
tions to identify persons who may have recently been infected and providing appropriate
evaluation and treatment (see Testing for TB Disease and Infection, p. 25 and Community
TB Control, p. 103).
Persons at Higher Risk for
Exposure to or Infection with TB
(cont.)
➤ Medically underserved, low-income populations
➤ High-risk racial or ethnic minority populations
➤ Children exposed to adults in high-risk categories
➤ Persons who inject illicit drugs
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Persons at Higher Risk of




➤ Persons with certain medical conditions
➤ Persons who inject illicit drugs
➤ History of inadequately treated TB
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Study Questions
Answers to these questions can be found in the text.
1. List four factors that contributed to the increase in reported TB cases from 1985 through
1992.
2. How has the number of reported TB cases changed recently?
3. Which racial and ethnic minorities are disproportionately affected by TB?
4. Why is multidrug-resistant TB a serious public health concern?
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Chapter Four
Testing for TB Disease and Infection
Summary. In most U.S. populations, targeted testing for TB is done to identify
persons at high risk for TB who would benefit from treatment for latent TB in-
fection (LTBI). Testing should be done in groups for which rates of TB are sub-
stantially higher than for the general population (targeted testing). All testing
activities should be accompanied by a plan for follow-up care for persons with
TB infection or disease. Clinicians should give tuberculin skin tests to high-risk
persons as part of their routine evaluation. Institutional testing is recommended
for the staff of health care facilities, as well as for the staff and residents of long-
term care institutions where TB cases are found. The Mantoux tuberculin skin
test is the preferred method of testing for TB infection.
Objectives
After working through this chapter, you will be able to
• List the 8 groups of persons who are at higher risk for exposure to or infection with
M. tuberculosis;
• List the 6 groups of persons who are at higher risk of developing TB disease once
infected with M. tuberculosis;
• Describe how the Mantoux tuberculin skin test is given;
• Describe the classification of the tuberculin reaction;
• Describe anergy testing and its role in tuberculin skin testing;
• Describe two-step testing.
Groups That Should Be Tested
In most U.S. populations, targeted testing for TB is done to find persons with infection and
disease who would benefit from treatment. Therefore, all testing activities should be accom-
panied by a plan for follow-up care of persons with LTBI or disease. Healthcare agencies or
other facilities should consult with the local health department before starting a skin-testing
program to ensure that adequate provisions are made for the evaluation and treatment of
persons whose tuberculin skin tests results are positive. Testing for TB infection should be
done in well-defined groups. These high-risk groups can be divided into two categories:
• Persons at higher risk for TB exposure or infection
• Persons at higher risk for TB disease once infected
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Groups that are not at high risk for TB should not be
tested routinely, because testing in low-risk populations
diverts resources from other priority activities and be-
cause positive tests in low-risk persons may not repre-
sent TB infection. Flexibility is needed in defining high-
priority groups for testing. The changing epidemiology
of TB indicates that the risk for TB among groups cur-
rently considered high priority may decrease over time,
and groups currently not identified as being at risk sub-
sequently may be considered as high priority.
In general, high-risk groups that should be tested for in-
fection include:
Persons at higher risk for TB exposure or
infection
• Close contacts of persons known or suspected to
have TB (i.e., those sharing the same household
or other enclosed environments)
• Foreign-born persons, including children, from ar-
eas that have a high TB incidence or prevalence
(e.g., Asia, Africa, Latin America, Eastern Europe,
Russia)
• Residents and employees of high-risk congregate
settings (e.g., correctional institutions, nursing
homes, mental institutions, other long-term resi-
dential facilities, and shelters for the homeless)
• Health care workers who serve high-risk clients
• Some medically underserved, low-income popu-
lations as defined locally
• High-risk racial or ethnic minority populations, de-
fined locally as having an increased prevalence of
TB (e.g., Asians and Pacific Islanders, Hispanics,
African Americans, Native Americans, migrant
farm workers, or homeless persons)
• Infants, children, and adolescents exposed to adults
in high-risk categories
• Persons who inject illicit drugs; any other locally





Purpose of Targeted Testing
➤ Find persons with LTBI who would benefit from
treatment
➤ Find persons with TB disease who would benefit
from treatment
➤ Groups that are not high risk for TB should not be
tested routinely
All testing activities should be
accompanied by a plan for follow-up
care.
Groups That Should Be Tested
for LTBI
Persons at higher risk for exposure to or infection with TB
➤ Close contacts of a person known or suspected to
have TB
➤ Foreign-born persons from areas where TB is
common
➤ Residents and employees of high-risk congregate
settings
➤ Health care workers (HCWs) who serve high-risk
clients
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Persons at higher risk for TB disease once infected
• Persons with HIV infection
• Persons who were recently infected with
M. tuberculosis (within the past 2 years), particu-
larly infants and very young children
• Persons who have medical conditions known to
increase the risk for disease if infection occurs,
e.g., diabetes, end stage renal disease (see Trans-
mission and Pathogenesis, p. 8)
• Persons who inject illicit drugs; other groups of
high-risk substance users (e.g., crack cocaine
users)
• Persons with a history of inadequately treated TB
The preferred method of testing for TB infection in adults
and children is the Mantoux tuberculin skin test. In some
circumstances, testing for TB disease with chest radio-
graphs or sputum smears may be more appropriate than
testing for infection with the tuberculin skin test. For ex-
ample, chest radiography is the preferred screening method
when the objective is to identify persons who have cur-
rent pulmonary TB and when treatment for LTBI is not
the primary goal (e.g., in high-turnover jails or in some
homeless shelters). Testing for TB infection or disease
should always be carried out in consultation with the health
department. Facilities such as drug treatment programs or
long-term care facilities should test high-risk groups only
when appropriate follow-up measures can be provided,
either by that facility or by the health department.
Clinicians should identify patients who are in a high-risk category (high risk for acquiring
infection or high risk of progressing to disease once infected), and they should give tubercu-
lin skin tests to these persons as part of their routine evaluation. In particular, persons with
certain medical conditions known to increase the risk for TB disease (see Transmission and
Pathogenesis, p. 8) should be tuberculin skin tested, and their tuberculin skin test status
should be clearly noted on their medical record. Pregnant women should be targeted for
tuberculin skin testing only if they have a specific risk factor for LTBI or for progression of
LTBI to disease. Persons with a positive reaction should be evaluated for TB disease and, if
disease is ruled out, considered for treatment for LTBI. For persons who have a positive
PPD and who have had TB disease ruled out, routine follow-up skin tests and chest radio-
graphs are unnecessary. These patients should be instructed to seek medical attention if they
experience signs and symptoms suggestive of active TB disease.
Groups That Should Be Tested
for LTBI (cont.)
Persons at higher risk for exposure to or infection with
TB
➤ Medically underserved, low-income
populations
➤ High-risk racial or ethnic minority populations
➤ Children exposed to adults in high-risk
categories
➤ Persons who inject illicit drugs
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Groups That Should Be Tested
for LTBI (cont.)
Persons at higher risk for TB disease once infected
➤ Persons with HIV infection
➤ Persons recently infected with M. tuberculosis
➤ Persons with certain medical conditions
➤ Persons who inject illicit drugs
➤ Persons with a history of inadequately treated
TB
SLIDE 30
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Figure 1. Administration of the tuberculin skin test
using the Mantoux method.
Health care workers in facilities or communities where TB cases have occurred should be
included in a TB testing and prevention program (see Infection Control in Health Care
Settings, p. 87). In addition, testing is recommended for the staff of congregate living facili-
ties who 1) may be exposed to persons with TB on the job (e.g., staff of correctional facili-
ties) or 2) would pose a risk to large numbers of susceptible persons if they developed
infectious TB (e.g., staff of AIDS hospices). Such persons should be tuberculin skin tested
upon employment and thereafter at intervals determined by the risk of transmission in that
facility. This testing is done for two reasons:
• To detect TB infection or disease in staff so that they may be given treatment
• To determine whether TB is being transmitted in the facility (indicated by skin test
conversions among staff)
Health care workers who have a documented history of a positive tuberculin skin test, ad-
equate treatment for disease, or adequate treatment for latent infection, should be exempt
from further tuberculin skin testing. Health care workers with positive tuberculin skin test
results should have a chest radiograph as part of the initial evaluation of their tuberculin
skin test; if negative, repeat chest radiographs are not needed unless symptoms develop that
could be attributed to TB. If health care workers with a documented history of a positive
tuberculin skin test develop signs and symptoms suggestive of TB, they should undergo a
medical evaluation including a chest radiograph. However, more frequent monitoring for
symptoms of TB may be considered for recent converters and other tuberculin skin test-
positive health care workers who are at increased risk for developing active TB (e.g., HIV-
positive or otherwise severely immunocompromised health care workers).
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Tuberculin Skin Testing
Administration of the Tuberculin Test
The Mantoux tuberculin skin test is the standard method
of identifying persons infected with M. tuberculosis. Mul-
tiple puncture tests (MPTs) should not be used to deter-
mine whether a person is infected. MPTs are not reliable
because the amount of tuberculin injected intradermally
cannot be precisely controlled. Tuberculin skin testing is
both safe and reliable throughout the course of pregnancy.
The Mantoux tuberculin test is performed by placing an
intradermal injection of 0.1 ml of purified protein deriva-
tive (PPD) tuberculin containing 5 tuberculin units (TU)
into the inner surface of the forearm (see figure 1). The
injection should be made with a disposable tuberculin sy-
ringe, just beneath the surface of the skin, with the needle
bevel facing upward. This should produce a discrete, pale
elevation of the skin (a wheal) 6 mm to 10 mm in diameter.
To prevent needle stick injuries, needles should not be re-
capped, purposely bent or broken, removed from dispos-
able syringes, or otherwise manipulated by hand. After
they are used, disposable needles and syringes should be
placed in puncture-resistant containers for disposal. Insti-
tutional guidelines regarding universal precautions for in-
fection control (e.g., the use of gloves) should be followed.
The reaction to the Mantoux test should be read by a trained
health care worker 48 to 72 hours after the injection (see
figure 2). Patients should never be allowed to read their
own tuberculin skin test results. If a patient fails to show
up for the scheduled reading, a positive reaction may still
be measurable up to 1 week after testing. However, if a
patient who fails to return within 72 hours has a negative test, tuberculin testing should be
repeated.
The area of induration (palpable raised hardened area) around the site of injection is the
reaction to tuberculin. The diameter of the indurated area should be measured across the
forearm (perpendicular to the long axis). Erythema (redness) should not be measured. All
reactions should be recorded in millimeters, even those classified as negative. If no indura-
tion is found, “0 mm” should be recorded. A tuberculin skin test conversion is defined as an
increase of ≥10 mm of induration within a 2-year period regardless of age.
Reading the Tuberculin Skin Test
➤ Read reaction 48-72 hours after injection
➤ Measure only induration




➤ Inject intradermally 0.1 ml of 5 TU PPD tuberculin
➤ Produce wheal 6 mm to 10 mm in diameter
➤ Do not recap, bend, or break needles, or remove
needles from syringes
➤ Follow universal precautions for infection control
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Classification of the Tuberculin
Reaction
A tuberculin reaction of ≥5 mm of
induration is classified as positive in
the following groups:
• HIV-positive persons
• Recent contacts of TB case
• Persons with fibrotic changes
on chest radiograph consistent
with old healed TB
• Patients with organ transplants
and other immunosuppressed
patients (receiving the equiva-
lent of ≥ 15 mg/day of pred-
nisone for ≥1 month)
A tuberculin reaction of ≥10 mm of induration is classi-
fied as positive in persons who do not meet the preceding
criteria but who have other risk factors for TB. These in-
clude:
• Recent arrivals (< 5 years) from high-prevalence
countries
• Injection drug users
• Residents and employees of high-risk congre-
gate settings: prisons and jails, nursing homes
and other long-term facilities for the elderly,
hospitals and other health-care facilities, resi-
dential facilities for AIDS patients, and home-
less shelters
• Mycobacteriology laboratory personnel
• Persons with clinical conditions that place them
at high risk (see Transmission and Pathogen-
esis, p. 8)
• Children < 4 years of age, or children and adoles-
cents exposed to adults in high-risk categories.
A tuberculin reaction of ≥15 mm of induration is classi-
fied as positive in persons with no known risk factors for
TB. However, targeted skin testing programs should only
be conducted among high-risk groups.
Figure 2. Correct measure of reaction to
the tuberculin skin test.
Classifying the Tuberculin Reaction
≥5 mm is classified as positive in
➤ HIV-positive persons
➤ Recent contacts of TB case
➤ Persons with fibrotic changes on chest
radiograph consistent with old healed TB
➤ Patients with organ transplants and other
immunosuppressed patients
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Classifying the Tuberculin Reaction (cont.)
≥10 mm is classified as positive in
➤ Recent arrivals from high-prevalence countries
➤ Injection drug users
➤ Residents and employees of high-risk congregate
settings
➤ Mycobacteriology laboratory personnel
➤ Persons with clinical conditions that place them at high
risk
➤ Children < 4 years of age, or children and adolescents
exposed to adults in high-risk categories
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In general, these guidelines for interpreting skin test re-
actions should also be applied to persons who may have
occupational exposure to TB (e.g., health care workers or
staff of nursing homes, drug treatment centers, or correc-
tional facilities). Thus, the appropriate cutoff for defining
a positive reaction depends on the employee’s individual
risk factors for TB, including recent TB exposure, and
the prevalence of TB in the facility. In facilities where the
risk of exposure is very low, ≥15 mm may be an appropriate
cutoff for employees with no other risk factors. In facilities
where TB patients receive care, ≥10 mm may be an appro-
priate cutoff for employees with no other risk factors.
The tuberculin skin test is a valuable tool, but it is not
perfect. Several factors can affect the skin test reaction
(see Table 1). Infection with mycobacteria other than M.
tuberculosis (nontuberculous mycobacteria) and vaccina-
tion with bacille Calmette-Guérin (BCG) can lead to false-
positive reactions (a positive skin test reaction in a person
not infected with M. tuberculosis). See BCG Vaccination,
p. 97, for further information on interpreting tuberculin re-
actions in persons with a history of BCG vaccination.
Vaccination with live viruses may also interfere with tu-
berculin skin test reactivity and cause false-negative re-
actions (a negative skin test reaction in a person infected
with M. tuberculosis). The Advisory Committee on Im-
munization Practices recommends that tuberculin skin
testing be done on either the same day as vaccination with
live-virus measles vaccine or 4-6 weeks after measles vac-
cination. 1 Other factors, such as anergy and overwhelm-
ing TB disease, can also lead to false-negative reactions.
Table 1
Factors that May Cause False-Positive and False-
Negative Reactions to the Tuberculin Skin Test
          Type of Reaction                                 Possible Cause
  False-positive Nontuberculous mycobacteria
BCG vaccination
  False-negative Anergy
Recent TB infection
Very young age (< 6 months old)
Live-virus vaccination
Overwhelming TB disease
Classifying the Tuberculin Reaction (cont.)
≥15 mm is classified as positive in
➤ Persons with no known risk factors for TB
➤ Targeted skin testing programs should only be
conducted among high-risk groups
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Occupational Exposure to TB,
Appropriate Cutoff Depends on
➤ Individual risk factors for TB
➤ Prevalence of TB in the facility
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Anergy Testing
The absence of a reaction to the tuberculin skin test does
not rule out the diagnosis of TB disease or infection. In
immunosuppressed persons, delayed-type hypersensitiv-
ity responses such as tuberculin reactions may decrease
or disappear. This condition, known as anergy, may be
caused by many factors, such as HIV infection, severe or
febrile illness, measles or other viral infections, Hodgkin’s
disease, sarcoidosis, live-virus vaccination, or the admin-
istration of corticosteroids or immunosuppressive drugs.
On average, 10% to 25% of patients with TB disease have
negative reactions when tested with a tuberculin skin test
at diagnosis before treatment. 2,3
Anergy is detected by administering at least two other delayed-type hypersensitivity anti-
gens by the Mantoux method of intradermal injection. The lack of standardization and out-
come data limit the evaluation of the effectiveness of anergy testing. The use of anergy
testing in conjunction with tuberculin skin testing is no longer routinely recommended for
testing programs for M. tuberculosis infection conducted among HIV-positive persons in
the United States.
Two-Step Testing
In some people who are infected with M. tuberculosis,
delayed-type hypersensitivity to tuberculin may wane over
the years. When these people are skin tested many years
after infection, they may have a negative reaction. How-
ever, this skin test may stimulate (boost) their ability to
react to tuberculin, causing a positive reaction to subse-
quent tests. This boosted reaction may be misinterpreted
as a new infection. The booster phenomenon may occur
at any age; its frequency increases with age and is high-
est among older persons. Boosted reactions may occur in
persons infected with nontuberculous mycobacteria or in
persons who have had a prior BCG vaccination.
Two-step testing is used to reduce the likelihood that a
boosted reaction will be misinterpreted as a recent infection. If the reaction to the first test is
classified as negative, a second test should be done 1 to 3 weeks later.  A positive reaction to
the second test probably represents a boosted reaction (past infection or prior BCG vaccina-
tion). On the basis of this second test result, the person should be classified as previously
infected and cared for accordingly. This would not be considered a skin test conversion. If
the second test result is also negative, the person should be classified as uninfected. In these
persons, a positive reaction to any subsequent test is likely to represent new infection with
M. tuberculosis (skin test conversion). Two-step testing should be used for the initial skin
Anergy
➤ Do not rule out diagnosis based on negative skin test
result
➤ Consider anergy in persons with no reaction if
➤ HIV infected
➤ Overwhelming TB disease




➤ Anergy skin testing no longer routinely recommended
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Boosting
➤ Some people with LTBI may have negative skin
test reaction when tested years after infection
➤ Initial skin test may stimulate (boost) ability to
react to tuberculin
➤ Positive reactions to subsequent tests may be
misinterpreted as a new infection
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testing of adults who will be retested periodically, such
as health care workers.
Because of cross-reactions with other mycobacteria, the
specificity of the tuberculin test is less when serial skin
testing is performed than when a single test is administered.
Thus, serial skin-testing programs tend to overestimate
the incidence of new TB infection in the tested popula-
tion. Because of this potential for overestimation of new
infections, serial skin-testing programs should be targeted




Use two-step testing for initial skin testing of adults
who will be retested periodically
➤ If first test positive, consider the person infected
➤ If first test negative, give second test 1-3 weeks
later
➤ If second test positive, consider person infected
➤ If second test negative, consider person
uninfected
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Study Questions
Answers to these questions can be found in the text.
1. What is the purpose of testing for TB infection and disease?
2. Name eight groups who are at higher risk for exposure to or infection with M. tuberculosis.
3. Name six groups who are at higher risk of developing TB disease once infected with
M. tuberculosis.
4. How is the Mantoux tuberculin skin test given? How is it read?
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5. What are the cutoffs (in millimeters of induration) for different groups?
6. What can cause a false-positive reaction? What can cause a false-negative reaction?
7. What is anergy?
8. When and why should two-step testing be done?
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Summary. The symptoms of pulmonary TB include cough, chest pain, and he-
moptysis; the specific symptoms of extrapulmonary TB depend on the site of
disease. Systemic symptoms consistent with TB include fever, chills, night sweats,
appetite loss, weight loss, and easy fatigability. The possibility of TB should be
considered in persons who have these symptoms. Persons suspected of having
TB should be referred for a medical evaluation, which should include a medical
history, a physical examination, a Mantoux tuberculin skin test, a chest radio-
graph, and any appropriate bacteriologic or histologic examinations. Positive
bacteriologic cultures for M. tuberculosis confirm the diagnosis of TB. Clini-
cians should not wait for bacteriologic culture results before starting therapy.
Therapy should be started when the potential risks of TB exceed the risk of
therapy.
Objectives
After working through this chapter, you will be able to
• List at least five symptoms of pulmonary TB;
• Explain the purpose and significance of the acid-fast bacilli (AFB) smear;
• Explain the purpose and significance of the culture;
• List at least four groups of persons who are at an increased risk for drug resistance.
Medical Evaluation
A complete medical evaluation for TB includes a medi-
cal history, a physical examination, a Mantoux tubercu-
lin skin test, a chest radiograph, and any appropriate bac-
teriologic or histologic examinations.
Medical History
The symptoms of pulmonary TB may include a produc-
tive, prolonged cough (duration of ≥ 3 weeks), chest pain,
and hemoptysis. Systemic symptoms of TB include fe-
ver, chills, night sweats, appetite loss, weight loss, and







➤ Mantoux tuberculin skin test
➤ Chest radiograph
➤ Bacteriologic or histologic exam
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Approximately 19% of TB cases are exclusively
extrapulmonary.1 The symptoms of extrapulmonary TB
depend on the site affected. TB of the spine may cause
pain in the back; TB of the kidney may cause blood in the
urine. Extrapulmonary TB should be considered in the
differential diagnosis of ill persons who have systemic
symptoms and who are at high risk for TB.
It is important to ask persons suspected of having TB about
their history of TB exposure, infection, or disease. Clini-
cians may also contact the local health department for
information about whether a patient has received TB treat-
ment in the past. If the drug regimen was inadequate or if
the patient did not adhere to therapy, TB may recur and
may be drug resistant. It is also important to consider de-
mographic factors (country of origin, age, ethnic or ra-
cial group, occupation) that may increase the patient’s
risk for exposure to TB or to drug-resistant TB disease.
In addition, clinicians should determine whether the pa-
tient has medical conditions, especially HIV infection,
that increase the risk for TB disease (see Transmission
and Pathogenesis, p. 8). All patients who do not know
their current HIV status should be referred for HIV coun-
seling and testing.
Physical Examination
A physical examination is an essential part of the evalua-
tion of any patient. It cannot be used to confirm or rule
out TB, but it can provide valuable information about the
patient’s overall condition and other factors that may
affect how TB is treated.
Tuberculin Skin Testing
The tuberculin skin test is useful for
• Examining a person who is not ill but may be
infected with M. tuberculosis, such as a person
who has been exposed to someone who has TB.
The tuberculin skin test is the only way to diag-
nose TB infection before the infection has pro-
gressed to TB disease;
• Determining how many people in a group are
infected with M. tuberculosis;
• Examining a person who has symptoms of TB.









Symptoms of Pulmonary TB





➤ Symptoms of disease
➤ History of TB exposure, infection, or disease
➤ Past TB treatment
➤ Demographic risk factors for TB
➤ Medical conditions that increase risk for TB
disease
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The preferred method of testing for TB infection in adults
and children is the Mantoux tuberculin skin test. The ad-
ministration of tuberculin using the Mantoux method and
interpretation of its results are discussed in Testing for TB
Disease and Infection, p. 25.
As noted in Testing for TB Disease and Infection, p. 25, a
negative reaction to the tuberculin skin test does not ex-
clude the diagnosis of TB, especially for patients with se-
vere TB illness or infection with HIV. Also, some persons
may not react to the tuberculin skin test if they are tested
too soon after being exposed to TB. In general, it takes 2
to 10 weeks after infection for a person to develop an im-
mune response to tuberculin. Persons who have recently
been around someone with TB and who have a negative
reaction to the tuberculin skin test should be retested 10
to 12 weeks after the last time they were exposed to infec-
tious TB. Children younger than 6 months of age may not
react to the tuberculin skin test because their immune sys-
tems are not yet fully developed.
Chest Radiograph
A posterior-anterior radiograph of the chest is the stan-
dard view used for the detection and description of chest
abnormalities. In some instances, other views (e.g., lat-
eral, lordotic) or additional studies (e.g., CT scans) may
be necessary.
In pulmonary TB, radiographic abnormalities are often
seen in the apical and posterior segments of the upper lobe
or in the superior segments of the lower lobe (see figure 1). However, lesions may appear
anywhere in the lungs and may differ in size, shape, density, and cavitation, especially in
HIV-positive and other immunosuppressed persons.
In HIV-infected persons, pulmonary TB may present atypically on the chest radiograph. For
example, TB may cause infiltrates without cavities in any lung zone, or it may cause medi-
astinal or hilar lymphadenopathy with or without accompanying infiltrates and/or cavities.
In HIV-positive persons, almost any abnormality on a chest radiograph may indicate TB. In
fact, the radiograph of an HIV-positive person with TB disease may even appear entirely
normal.
Old healed tuberculosis usually presents a different radiographic appearance from active
tuberculosis. Old healed tuberculosis can produce various radiographic findings. Dense
pulmonary nodules, with or without visible calcification, may be seen in the hilar area or
upper lobes. Smaller nodules, with or without fibrotic scars, are often seen in the upper
lobes. Upper-lobe volume loss often accompanies these scars. Nodules and fibrotic lesions
Mantoux Tuberculin Skin Test
➤ Preferred method of testing for TB infection in
adults and children
➤ Tuberculin skin testing useful for
➤ Examining person who is not ill but may be
infected
➤ Determining how many people in group are
infected
➤ Examining person who has symptoms of TB
Chest Radiograph
➤ Abnormalities often seen in apical or posterior
segments of upper lobe or superior segments of
lower lobe
➤ May have unusual appearance in HIV-positive
persons
➤ Cannot confirm diagnosis of TB
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of old healed tuberculosis have well-demarcated, sharp
margins and are often described as “hard.” Bronchiecta-
sis of the upper lobes is a nonspecific finding that some-
times occurs from previous pulmonary tuberculosis.
Pleural scarring may be caused by old tuberculosis, but
is more commonly caused by trauma or other infections.
Nodules and fibrotic scars may contain slowly multi-
plying tubercle bacilli with the potential for future pro-
gression to active tuberculosis.  The risk of progression
is significant, and persons who have nodular or fibrotic
lesions consistent with findings of old tuberculosis on
chest radiograph and have a positive tuberculin skin test
reaction should be considered high-priority candidates
for treatment of latent infection regardless of age. Con-
versely, calcified nodular lesions (calcified granuloma)
pose a very low risk for future progression to active
tuberculosis.
Abnormalities on chest radiographs may be suggestive of, but are never diagnostic of, TB.
However, chest radiographs may be used to rule out the possibility of pulmonary TB in a
person who has a positive reaction to the tuberculin skin test and no symptoms of disease.
Diagnostic Microbiology
Specimen Collection
Persons suspected of having pulmonary or laryngeal TB
should have at least three sputum specimens examined
by smear and culture. It is best to obtain a series of early-
morning specimens collected on 3 consecutive days.
Specimens should be obtained in an isolated, well-venti-
lated area or a sputum collection booth.
A health care worker should coach and directly super-
vise the person at least the first time sputum is collected.
Persons should be properly instructed in how to produce
a good specimen. Patients should be informed that spu-
tum is the material brought up from the lungs and that
mucus from the nose or throat and saliva are not good
specimens. Coaching patients individually on how to expectorate can facilitate sputum col-
lection. Unsupervised patients are seldom successful in providing an adequate specimen,
especially the first time. The amount of coaching required on later visits will depend on
individual patient needs.
Figure 1. Arrow points to
a cavity in patient’s right
upper lobe.
Specimen Collection
➤ Obtain 3 sputum specimens for smear
examination and culture
➤ Persons unable to cough up sputum, induce
sputum, bronchoscopy or gastric aspiration
➤ Follow infection control precautions during
specimen collection
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For patients unable to cough up sputum, deep coughing may be induced by inhalation of an
aerosol of warm, hypertonic (5%-15%) saline. Patients should be given time — 15 minutes
is usually sufficient — to produce sputum, which is usually brought up by a deep cough.
Because induced sputum is very watery and resembles saliva, it should be labeled “in-
duced” to ensure that the laboratory staff do not discard it.
Bronchoscopy can be done if there is suspicion of TB and the patient cannot cough up
sputum. Adequate infection control precautions should be taken when performing a bron-
choscopy for the purpose of diagnosing TB disease (see Infection Control in Health Care
Settings, p. 87). Bronchial washings, brushings, and biopsy specimens may be obtained,
depending on the diagnostic possibilities and findings. Sputum collected after bronchos-
copy may also be useful for a diagnosis.
Gastric aspiration can also be used to obtain specimens of swallowed sputum. Although it is
uncomfortable, it is more cost effective and less invasive then bronchoscopy. It is the best
way to obtain specimens from infants and some young children who cannot produce spu-
tum even with aerosol inhalation. When using gastric aspiration to obtain specimens from
children, it should be done in the morning before the patient gets out of bed or eats.
During specimen collection, patients produce an aerosol that may be hazardous to health
care workers or other patients in close proximity. For this reason, precautionary measures
for infection control must be followed during sputum induction, bronchoscopy, and other
common diagnostic procedures (see Infection Control in Health Care Settings, p.87).
Because TB can occur in almost any anatomical site, a variety of clinical specimens other
than sputum (e.g., urine, cerebrospinal fluid, pleural fluid, pus, or biopsy specimens) may
be submitted for examination when extrapulmonary TB disease is suspected. Tissue speci-
mens for the culture of M. tuberculosis should be placed in a transport medium (e.g., Dubos)
or a normal saline solution. Formalin or other preservatives should not be used because
these solutions kill or inhibit the growth of M. tuberculosis. Tissue specimens should be
delivered to the laboratory promptly.
Laboratory Examination
Detection of acid-fast bacilli (AFB) in stained smears ex-
amined microscopically may provide the first bacterio-
logic clue of TB (see figure 2). Fluorochrome staining
with auramine-rhodamine is the preferred staining method
because it is faster than the traditional methods in which
Ziehl-Neelsen or Kinyoun (basic fuchsin dye) stains are
used. Smear examination is an easy and quick procedure;
results should be available within 24 hours of specimen
collection. However, smear examination permits only the
presumptive diagnosis of TB because the AFB in a smear
may be mycobacteria other than M. tuberculosis. Further-
more, many TB patients have negative AFB smears.
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Smear Examination
➤ Strongly consider TB in patients with smears
containing acid-fast bacilli (AFB)
➤ Results should be available within 24 hours of
specimen collection
➤ Presumptive diagnosis of TB
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Positive cultures for M. tuberculosis
confirm the diagnosis of TB; however,
TB may also be diagnosed on the ba-
sis of clinical signs and symptoms in
the absence of a positive culture. Cul-
ture examinations should be done on
all specimens, regardless of AFB smear
results (figure 3).  The BACTEC Ra-
diometric System or other recently de-
veloped liquid medium systems allow
detection of mycobacterial growth in
4 to 14 days. 2, 3
Once the mycobacteria have been
grown in culture, nucleic acid probes
can identify the species in 2 to 4 hours.4
Nucleic acid probes specific for the M.
tuberculosis complex, for M. avium,
and for M. intracellulare provide a
rapid method of species identification.
High-performance liquid chromatog-
raphy (HPLC), which detects differ-
ences in the spectrum of mycolic ac-
ids in the cell wall, is equally rapid and
can identify most pathogenic myco-
bacterial species.5 A test for inhibition
by ρ-nitro-α-acetylamino-β-hydro-
xypropio-phenone (NAP or NAP test)
can identify M. tuberculosis in 3 to 4 days.4 If a solid
medium and conventional biochemical tests are used, the
isolation and identification of the organism can take 6 to
12 weeks.3
Nucleic acid amplification (NAA) tests, such as poly-
merase chain reaction (PCR) and other methods for am-
plifying DNA and RNA, may facilitate rapid detection of
microorganisms. Commercial NAA kits for the identifi-
cation of M. tuberculosis complex have been approved
by the Food and Drug Administration (FDA) for use on
processed clinical specimens. These tests perform worst
where needed most. Specificity is inadequate when ap-
plied to smear-negative specimens and sensitivity is in-
adequate when applied to smear-positive specimens. The
test is approved for use in conjunction with culture for
respiratory specimens that are positive for AFB on microscopy and were obtained from
untreated patients. When used as approved, a positive NAA test result indicates a high
likelihood of TB, but a negative result does not exclude TB. However, a reformulated
Figure 2. AFB (shown in red) are
tubercle bacilli.




➤ Use to confirm diagnosis of TB
➤ Culture all specimens, even if smear negative
➤ Results in 4 to 14 days when liquid medium
systems used
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AMPLIFIED Mycobacterium Tuberculosis Direct (MTD) Test for the detection of M. tu-
berculosis in both smear-positive and smear-negative clinical specimens has recently been
approved. This is the first NAA test approved for this indication. Decisions about when and
how to use NAA tests for TB diagnosis should be individualized. NAA tests cannot replace
clinical judgment or be relied on as the only guide for therapy or isolation practices. The
tests may enhance diagnostic certainty, but should be interpreted in a clinical context and on
the basis of local laboratory performance.
Follow-up bacteriologic examinations are important for assessing the patient’s infectious-
ness and response to therapy. At a minimum, specimens should be obtained at monthly
intervals until the culture results convert to negative. Culture conversion is the most impor-
tant objective measure of response to treatment. Conversion is documented by the first nega-
tive culture in a series of cultures (i.e., all subsequent culture results must remain negative).
Laboratories should report positive smears and positive cultures within 24 hours by tele-
phone or fax to the primary health care provider. Out-of-state laboratories must contact the
health care provider in the patient’s state of origin. Follow-up results may be reported by
mail. It is the responsibility of the primary health care
provider to promptly report all suspected or confirmed
cases of TB to the health department so that a contact
investigation can be initiated as quickly as possible (see
Community TB Control, p. 103).
For all patients, the initial M. tuberculosis isolate should
be tested for drug resistance. It is crucial to identify drug
resistance as early as possible in order to ensure appropri-
ate treatment. Susceptibility results from laboratories
should be promptly forwarded to the health department.
Drug susceptibility patterns should be repeated for pa-
tients who do not respond adequately or who have posi-
tive culture results despite 2 months of therapy.
The BACTEC radiometric method, which uses a liquid
medium, is faster than conventional methods for deter-
mining susceptibility to first-line TB medications. Usu-
ally, susceptibility results can be obtained within 7-14 days
of BACTEC inoculation; conventional methods, which
use solid media for growth, can take as long as 21 days
after inoculation.2, 3
Groups at an increased risk for drug resistance include
• Persons who have a history of treatment with TB
drugs;
• Contacts of persons known to have drug-resistant
TB;
Drug Susceptibility Testing
➤ Drug susceptibility testing on initial M.
tuberculosis isolate
➤ Repeat for patients who
➤ Do not respond to therapy
➤ Have positive cultures despite 2 months of
therapy
➤ Promptly forward results to the health department
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Persons at Increased Risk for Drug
Resistance
➤ History of treatment with TB drugs
➤ Contacts of persons with drug-resistant TB
➤ Foreign-born persons from high prevalent drug
resistant areas
➤ Smears or cultures remain positive despite 2
months of TB treatment
➤ Received inadequate treatment regimens for > 2
weeks
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• Foreign-born persons from areas where the prevalence of drug-resistant TB is high;
• Persons whose smears or cultures remain positive despite 2 months of therapy with
TB drugs;
• Persons receiving inadequate treatment regimens for > 2 weeks.
Restriction fragment length polymorphism (RFLP), a method of DNA fingerprinting, can
be used to identify specific strains of M. tuberculosis and thus track TB transmission during
outbreaks. The restriction enzymes used in this technique cut DNA at certain sites to pro-
duce fragments of various lengths. These fragments are separated by size to produce a
pattern, or “fingerprint,” that is specific for each strain. Related isolates show the same
pattern. In addition, DNA fingerprinting can be used to detect lab contamination by deter-
mining if the isolates from the contaminating source culture and the suspect culture are
related. If the isolates have differing DNA fingerprint patterns, cross-contamination is very
unlikely to have taken place.
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Study Questions
Answers to these questions can be found in the text.
1. What are the components of a complete medical evaluation for TB?
2. List the symptoms of pulmonary TB.
3. What is the tuberculin skin test useful for?
4. What are the purposes of the chest radiograph?
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5. What is the purpose of an acid-fast bacilli smear?
6. What is the purpose of the culture?
7. Why are drug susceptibility tests done? How often should they be done?
8. What groups of persons are at an increased risk for drug resistance?
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Summary. Treatment of latent TB infection (LTBI) is essential to controlling
and eliminating TB in the United States. Treatment of LTBI substantially re-
duces the risk that TB infection will progress to disease. Certain groups are at
very high risk of developing TB disease once infected. Targeted testing pro-
grams should be designed to identify persons who are at high risk for TB and
who would benefit from treatment of LTBI. There are several treatment regi-
mens available for the treatment of LTBI, and providers should discuss treat-
ment options with their patients. Baseline laboratory testing is not routinely indi-
cated for all patients at the start of treatment for LTBI. Baseline hepatic measure-
ments of serum AST (SGOT) or ALT (SGPT) and bilirubin are indicated for
patients whose initial evaluation suggests an increased risk for liver disease.
Objectives
After working through this chapter, you will be able to
• List the high-risk groups who should be given high priority for treatment of latent
TB infection;
• Describe the treatment-of-latent-TB-infection regimens for HIV-positive and HIV-
negative persons;
• Describe how patients should be monitored.
Treatment of latent TB infection (LTBI) is essential to controlling and eliminating TB in the
United States. Treatment of LTBI substantially reduces the risk that TB infection will progress
to disease. Certain groups are at very high risk of developing TB disease once infected, and
every effort should be made to begin appropriate treatment and to ensure those persons
complete the entire course of treatment for LTBI.
Candidates for Treatment of Latent TB Infection
Targeted testing programs should be designed to identify persons who are at high risk for
TB and who would benefit from treatment of LTBI. Careful assessment to rule out the
possibility of TB disease is necessary before treatment for LTBI is started.
Persons in the following high-risk groups should be given treatment for LTBI if they have
positive skin test results (≥5 mm):
• HIV-positive persons;
• Recent contacts of a TB case;
• Persons with fibrotic changes on chest radiograph consistent with old TB;
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• Patients with organ transplants, and other im-
munosuppressed patients (receiving the equiva-
lent of ≥15 mg/day of prednisone for ≥1 month).
In addition, persons in the following high-risk groups
should be considered for treatment of LTBI if their reac-
tion to the tuberculin skin test is ≥10 mm:
• Recent arrivals (< 5 years) from high-prevalence
countries;
• Injection drug users;
• Residents and employees of high-risk congre-
gate settings (e.g., correctional facilities, nurs-
ing homes, homeless shelters, hospitals, and
other health care facilities);
• Mycobacteriology laboratory personnel;
• Persons with clinical conditions that make them
high-risk (see Transmission and Pathogenesis,
p 8);
• Children < 4 years of age, or children and adoles-
cents exposed to adults in high-risk categories.
No Known Risk Factors
Persons with no known risk factors for TB may be con-
sidered for treatment of LTBI if their reaction to the tu-
berculin test is ≥15 mm. This group should be given a
lower priority for prevention efforts than the groups listed
above.
Close Contacts
Some contacts who have a negative tuberculin skin test
reaction (less than 5 mm of induration) should be evalu-
ated for treatment of LTBI, after TB disease has been ruled
out. These contacts include children under 4 years of age,
immunosuppressed people, and others who may develop
TB disease quickly after infection. Close contacts who
have a negative reaction to an initial skin test should be
retested 10 to 12 weeks after they were last exposed to
TB. Treatment of latent infection may be discontinued if
the skin test result is again negative and if the person is
no longer exposed to TB. However, persons known to
have or suspected of having HIV infection and other
immunocompromised persons should be given treatment




Candidates for Treatment of LTBI
Positive skin test result ≥5 mm
➤ HIV-positive persons
➤ Recent contacts of a TB case
➤ Persons with fibrotic changes on chest
radiograph consistent with old TB
➤ Patients with organ transplants and other
immunosuppressed patients
Candidates for Treatment of LTBI
(cont.)
Positive skin test result ≥10 mm
➤ Recent arrivals from high-prevalence countries
➤ Injection drug users
➤ Residents and employees of high-risk congregate
settings
➤ Mycobacteriology laboratory personnel
➤ Persons with clinical conditions that make them high-risk
➤ Children < 4 years of age, or children and adolescents
exposed to adults in high-risk categories
Candidates for Treatment of LTBI
(cont.)
Positive skin test result ≥15 mm
➤ Persons with no known risk factors for TB may be
considered
➤ Targeted skin testing programs should only be
conducted among high-risk groups
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Children and Adolescents
Because or their age, infants and young children with LTBI are known to have been infected
recently, and thus are at a high risk of their infection progressing to disease. Infants and
young children are also more likely than older children and adults to develop life-threaten-
ing forms of TB. Children < 4 years of age who are close contacts should receive treatment
for LTBI even if the tuberculin skin test result and chest radiograph do not suggest TB,
because infected infants may be anergic as late as 6 months of age. A second tuberculin test
should be placed 10-12 weeks after the last exposure to infectious TB. Treatment of LTBI
can be discontinued if all of the following conditions are met:
• The infant is at least 6 months of age;
• The second tuberculin test is also negative;
• The second test was performed at least 10 weeks after the child was last exposed to
infectious TB.
Regimens
(See tables 1 [pp. 112-113] and 2 [pp. 114-115])
There are several treatment regimens available for the treatment of LTBI, and providers
should discuss options with their patients. For persons who are at especially high risk for
TB and are either suspected of nonadherence or are on an intermittent dosing regimen,
directly observed therapy (DOT) of LTBI should be considered. This method of treatment is
especially appropriate when a household member is on DOT for active disease, or in insti-
tutions and facilities where treatment for infection can be observed by a staff member.
Isoniazid
In clinical trials, daily isoniazid treatment for latent infec-
tion for 12 months reduced the risk for TB disease by more
than 90% in patients who completed a full course of
therapy.1 There is evidence that 6 months of treatment for
LTBI with isoniazid can also confer a high degree of pro-
tection (approximately 70% in patients who complete the
regimen) against the progression of TB infection to TB
disease.1 The protection conferred by taking at least 9
months of isoniazid is greater than that conferred by tak-
ing 6 months.
Isoniazid is normally used alone for treatment of LTBI in
a single daily dose of 300 mg in adults and 10-15 mg/kg
body weight in children, not to exceed 300 mg per dose.
Isoniazid can be given two times a week at a dosage of 15 mg/kg as DOT of LTBI.2,3 When
isoniazid is given alone to persons with active TB disease, resistance to isoniazid is likely to
develop. For this reason, persons suspected of having TB disease should receive the recom-
mended multidrug regimen for treatment of disease until the diagnosis is confirmed or ruled out.
SLIDE 58
Treatment of LTBI with
Isoniazid (INH)
➤ 9-month regimen considered optimal
➤ Children should receive 9 months of therapy
➤ Can be given twice-weekly if directly observed
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A 9-month regimen (minimum of 270 doses administered within 12 months) is considered
optimal treatment for both HIV-positive and HIV-negative adults. A 6-month regimen (mini-
mum of 180 doses administered within 9 months) may also provide sufficient protection.
HIV-positive and HIV-negative children should receive 9 months of isoniazid treatment for
infection. Twice-weekly regimens should consist of at least 76 doses administered within
12 months for the 9-month regimen and 52 doses within 9 months for the 6-month regimen.
Treatment for LTBI for 6 months rather than 9 months may be more cost-effective and
result in greater adherence by patients, therefore, local programs may prefer to implement
the 6-month regimen rather then the 9-month regimen. Every effort should be made to
ensure that patients adhere to treatment for infection for at least 6 months.
Peripheral neuropathy is associated with the use of isoniazid but is uncommon at doses of 5
mg/kg. Persons with conditions in which neuropathy is common (e.g., diabetes, uremia,
alcoholism, malnutrition, HIV-infection), as well as pregnant women and persons with a
seizure disorder, may be given pyridoxine (vitamin B
6
) (10-50 mg/day) with isoniazid.
Rifampin/Pyrazinamide
Two- and three-month regimens with daily rifampin in
combination with pyrazinamide and/or isoniazid have re-
cently been evaluated in HIV-positive adult patients and
appear to be as effective as longer courses of isoniazid.2,3
Clinical trials of rifampin and pyrazinamide have not been
conducted in HIV-negative persons. Therefore, the
strength of the recommendation for use of this regimen is
less for this population than for those who are HIV-posi-
tive.  Regimens consisting of 2 months of rifampin and
pyrazinamide are not recommended for pregnant women.
Pyrazinamide’s effect on the fetus is unknown.
HIV-Negative Persons
The recommended 2-month treatment-of-latent-infection
regimen (60 doses to be administered within 3 months) includes daily rifampin and pyrazi-
namide. Rifampin is given in a daily dose of 10 mg/kg (maximum dose 600 mg) and pyrazi-
namide is given in a daily dose of 15-20 mg/kg (maximum dose 2 g). Rifampin and pyrazi-
namide may also be given two times a week (16 doses to be administered for 2 months or 24
doses to be administered for 3 months). However, this regimen has not been studied in this
population and should be used only when other effective regimens cannot be given. Like all
intermittent regimens, this regimen must always be administered under DOT.
HIV-Positive Persons
Two-month regimens for treatment of LTBI that include rifampin or rifabutin are appropri-
ate for HIV-positive adults who are likely to be infected with TB organisms susceptible to
rifamycins.
The administration of rifampin is contraindicated with some protease inhibitors (PIs) and
nonnucleoside reverse transcriptase inhibitors (NNRTIs) used for HIV therapy. For these
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Treatment of LTBI with a Rifamycin and
Pyrazinamide (PZA)
HIV-Positive Persons
➤ A rifamycin and PZA daily for 2 months
➤ May be given twice weekly
➤ Administration of rifampin (RIF) contraindicated with some
protease inhibitors (PIs) and nonnucleoside reverse
transcriptase inhibitors (NNRTIs).
HIV-Negative Persons
Clinical trials have not been conducted
➤ Daily RIF and PZA for 2 months
➤ May be given twice weekly
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patients, a substitution of rifabutin for rifampin is generally recommended. Clinicians are
advised to consider potential drug interactions when prescribing rifamycins to patients re-
ceiving HIV therapy with PIs and NNRTIs. Daily regimens of a rifamycin (rifampin or
rifabutin) and pyrazinamide should consist of at least 60 doses to be administered for 2
months or up to 3 months. This regimen may also be given two times a week (16 doses to be
administered for 2 months or 24 doses to be administered for 3 months).
For HIV-positive patients receiving PIs or NNRTIs, an alternative 2-month regimen in-
cludes rifabutin and pyrazinamide administered daily. However, the concurrent adminis-
tration of rifabutin is contraindicated with hard-gel saquinavir and delavirdine. An alterna-
tive is the use of rifabutin with indinavir, nelfinavir, amprenavir, ritonavir, efavirenz, and
possibly soft-gel saquinavir and nevirapine. Caution is advised when using rifabutin with
soft-gel saquinavir and nevirapine, because data regarding the use of rifabutin with soft-
gel saquinavir and nevirapine are limited. Rifabutin is given in a daily dose of 5 mg/kg
(maximum dose 300 mg) and pyrazinamide is given in a daily dose of 15-20 mg/kg (maxi-
mum dose 2 g). The dosage of rifabutin may need to be adjusted when given with certain
PIs and NNRTIs (see table 5, pp. 120-121).
For HIV-positive patients not receiving PIs or NNRTIs, the recommended 2-month treat-
ment-of-latent-infection regimen includes daily rifampin and pyrazinamide. Rifampin is
given in a daily dose of 10-20 mg/kg (maximum dose 600 mg) and pyrazinamide is given in
a daily dose of 15-20 mg/kg (maximum dose 2 g).
Rifampin
For both HIV-negative and HIV-positive patients who cannot tolerate isoniazid or pyrazina-
mide, an alternative treatment regimen is 4-months (minimum of 120 doses administered
within 6 months) of rifampin.
Regimens for Specific Situations
Contacts of Isoniazid-Resistant TB
For persons who are known to be contacts of patients with
isoniazid-resistant, rifampin-susceptible TB, a 2-month
regimen of rifampin and pyrazinamide is recommended.
For patients who are unable to tolerate pyrazinamide, a
4-month regimen of daily rifampin alone is recommended.
In situations where rifampin cannot be used, rifabutin may
be substituted. For HIV-positive persons, a 2-month regi-
men with a rifamycin and pyrazinamide is recommended.
Contacts of Multidrug-Resistant TB
For persons likely to have been infected with a strain of
M. tuberculosis resistant to both isoniazid and rifampin,
alternative regimens should be considered. Alternative
SLIDE 60
Contacts of INH-Resistant TB
➤ Treatment with a rifamycin and PZA
➤ If unable to tolerate PZA, 4-month regimen of daily RIF
➤ HIV-positive persons: 2 month regimen with a rifamycin
and PZA
Contacts of Multidrug-Resistant TB
➤ Use 2 drugs to which the infecting organism has
demonstrated susceptibility
➤ Treat for 6 months or observe without treatment (HIV-
negative)
➤ Treat HIV-positive persons for 12 months
➤ Follow for 2 years regardless of treatment
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regimens should consist of two drugs to which the infecting organism has demonstrated
susceptibility. Potential alternative regimens include either 6-12 months of daily ethambu-
tol and pyrazinamide or 6-12 months of pyrazinamide and a quinolone (i.e, levofloxacin,
ofloxacin, or ciprofloxacin). Immunocompetent contacts may be treated for 6 months or
observed without treatment. Immunocompromised contacts (e.g., HIV-positive persons)
should be treated for 12 months. Persons receiving pyrazinamide and a quinolone antibiotic
should be monitored closely for adverse effects. Some evidence suggests that the combina-
tion of pyrazinamide and ofloxacin may be poorly tolerated.4 All persons with suspected
multidrug-resistant LTBI should be followed for 2 years regardless of the treatment regimen.
Ethambutol at the usual dose is safe for children. The regimen of pyrazinamide and etham-
butol for 9-12 months is recommended for children if the infecting organism has demon-
strated susceptibility. When pyrazinamide and/or ethambutol cannot be used, a combina-
tion of two other drugs to which the infecting organism is likely susceptible is recommended.
Persons with Fibrotic Lesions
Patients who have a chest radiograph suggestive of old fibrotic lesions thought to represent
previous TB, a positive tuberculin skin test (≥5 mm), no evidence of active disease, and no
history of treatment for TB should be treated for LTBI. Acceptable regimen options include
• 9 months of isoniazid
• 2 months of rifampin plus pyrazinamide or
• 4 months of rifampin (with or without isoniazid)
Patients who have a positive tuberculin skin test and ra-
diographic findings suggestive of healed, primary TB (cal-
cified solitary pulmonary nodules, calcified hilar lymph
nodes, and apical pleural capping) are not at significantly
increased risk of TB. Their risk for progression to TB
disease and the need for treatment of LTBI should be de-
termined by other risk factors and the size of the tubercu-
lin reaction.
Pregnancy and Breast-feeding
Isoniazid administered either daily or twice-weekly are
the preferred regimens for the treatment of LTBI in preg-
nant women. Such women taking isoniazid should also
take pyridoxine (vitamin B
6
) supplementation. Although
rifampin may be safe, there are no efficacy data support-
ing its use in this population.
For women who are at high risk for the progression of LTBI to active disease, especially
those who are HIV-positive or who have been recently infected, initiation of therapy should
not be delayed on the basis of pregnancy alone, even during the first trimester. For these




➤ 9 months of INH
➤ 2 months RIF plus PZA
➤ 4 months of RIF (with or without INH)
Pregnancy and Breast-feeding
➤ INH daily or twice weekly
➤ Pyridoxine supplementation
➤ Breast-feeding not contraindicated
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Breast-feeding is not contraindicated when a mother is being treated for LTBI. Likewise,
the amount of isoniazid provided by breast milk is inadequate for the treatment of an infant.
Infants whose breast-feeding mothers are taking isoniazid should receive supplemental py-
ridoxine.
Monitoring
Before treatment for LTBI is started, clinicians should con-
duct a medical history to
• Rule out the possibility of TB disease;
• Determine the history of treatment for LTBI or
disease;
• Determine if there are any preexisting medical
conditions that are a contraindication to treatment
or are associated with an increased risk of adverse
effects of treatment;
• Obtain information about current and previous
drug therapy, including any previous adverse re-
actions to drugs considered for treatment of LTBI
and to current drugs which have known interac-
tions with drugs used for the treatment of LTBI;
• Recommend HIV testing if risk factors are
present.
In addition, conducting a medical history provides an op-
portunity to establish rapport with the patient and to high-
light important aspects of treatment, such as
• Benefits of treatment
• Importance of adherence to the treatment regimen
• Possible adverse side effects of the regimen
• Establishment of an optimal follow-up plan
Baseline laboratory testing is not routinely indicated for
all patients at the start of treatment for LTBI. Baseline
hepatic measurements of serum AST (SGOT) or ALT
(SGPT) and bilirubin are indicated for patients whose initial evaluation suggests a liver
disorder. Baseline testing is also indicated for patients with HIV infection, women who are
pregnant or in the immediate postpartum period (within 3 months of delivery), and persons
with a history of chronic liver disease (e.g., hepatitis B or C, alcoholic hepatitis or cirrhosis,
persons who use alcohol regularly, and others who are at risk of chronic liver disease).
Baseline laboratory testing is not routinely indicated in older persons. However, testing
may be considered on an individual basis, particularly for patients who are taking other
Monitoring Patients
Before treatment for LTBI is started, clinicians should
➤ Rule out possibility of TB disease
➤ Determine history of treatment for LTBI or
disease
➤ Determine contraindications to treatment
➤ Obtain information about current and previous
drug therapy
➤ Recommend HIV testing if risk factors are present
Monitoring Patients (cont.)
Establish rapport with patient and emphasize
➤ Benefits of treatment
➤ Importance of adherence to treatment regimen
➤ Possible adverse side effects of regimen
➤ Establishment of optimal follow-up plan
SLIDE 62
SLIDE 63
60 Core Curriculum on Tuberculosis
medications for chronic medical conditions. Active hepati-
tis and end-stage liver disease are relative contraindications
to the use of isoniazid or pyrazinamide for treatment of
LTBI. Use of these drugs in such patients must be under-
taken with caution.
At least once a month, clinicians should evaluate patients
receiving treatment of LTBI for
• Adherence to the prescribed regimen
• Signs and symptoms of active TB disease
• Signs and symptoms of hepatitis (if receiving
isoniazid alone, and at 2, 4, and 8 weeks if
receiving rifampin and pyrazinamide)
Routine laboratory monitoring during treatment of LTBI
is indicated only for those whose baseline liver function
tests are abnormal and for other persons with a risk of
hepatic disease. There should be laboratory testing, such
as liver function studies for patients with symptoms com-
patible with hepatotoxicity or a uric acid measurement to
evaluate patients who develop acute arthritis, to evaluate
possible adverse reactions that occur during the treatment
regimen.
Some evidence suggests that women, particularly black
and Hispanic women, are at increased risk for fatal hepa-
titis associated with isoniazid.5 This risk may also be in-
creased during the postpartum period. These persons
should be closely monitored for adverse reactions
throughout the course of treatment.
About 10% to 20% of persons taking isoniazid will have some mild, asymptomatic eleva-
tion of liver enzymes. These abnormalities tend to resolve even if isoniazid is continued. If
any of the measurements exceed three to five times the upper limit of normal or if the





➤ Not routinely indicated
➤ Baseline hepatic measurements for
➤ Patients whose initial evaluation suggests a
liver disorder
➤ Patients with HIV infection
➤ Pregnant women and those in immediate
postpartum period
➤ Patients with history of chronic liver disorder
Monitoring Patients (cont.)
At least monthly, evaluate for
➤ Adherence to prescribed regimen
➤ Signs and symptoms of active TB disease
➤ Signs and symptoms of hepatitis (if receiving
isoniazid alone, and at 2, 4, and 8 weeks if
receiving RIF and PZA)
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Study Questions
Answers to these questions can be found in the text.
1. Which groups of persons should receive high priority for treatment of LTBI?
2. What are the recommended regimens for treatment of LTBI for HIV-positive patients?
3. What are the recommended regimens for treatment of LTBI for HIV-negative patients?
4. Which patients should receive baseline laboratory testing?
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Summary. For most patients, the preferred regimen for treating TB disease
consists of an initial 2-month phase of four drugs: isoniazid, rifampin, pyrazina-
mide, and ethambutol followed by a 4-month continuation phase of isoniazid
and rifampin. Streptomycin may be substituted for ethambutol, but must be given
by injection. Ethambutol (or streptomycin) can be discontinued when drug sus-
ceptibility results show the infecting organism to be fully drug-susceptible. In
areas where the rate of isoniazid resistance is documented to be less than 4% and
the patient has had no previous treatment with TB drugs, is not from a country
with a high prevalence of drug resistance, and has no known exposure to a pa-
tient with drug-resistant disease, three drugs (isoniazid, rifampin, and pyrazina-
mide) may be adequate for the initial regimen. TB treatment regimens may need
to be altered for HIV-positive patients taking HIV protease inhibitors. Whenever
possible, the care for HIV-related TB should be provided by or in consultation
with experts in the management of both TB and HIV disease. The major deter-
minant of the outcome of treatment is patient adherence to the drug regimen.
Thus, careful attention should be paid to measures designed to foster adherence,
and treating all patients with directly observed therapy (DOT) is strongly recom-
mended. Multidrug-resistant TB (i.e., TB resistant to both isoniazid and rifampin)
presents difficult treatment problems and requires expert consultation.
Objectives
After working through this chapter, you will be able to
• Describe the recommended regimen for the initial treatment of TB in HIV-negative
persons;
• Describe the recommended TB treatment regimens for HIV-positive persons;
• Explain why case management and directly observed therapy are important;
• List the common adverse reactions to the drugs used to treat TB;
• Describe how patients should be evaluated for their response to treatment.
Chapter Seven
Treatment of TB Disease
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TB must be treated for a long time (at least 6 months for
most patients) compared with many other infectious dis-
eases. If treatment is not continued for a sufficient length
of time, some tubercle bacilli may survive and the patient
may become ill and infectious again. Regimens for the
treatment of TB must contain multiple drugs to which the
organisms are susceptible. Treatment with a single drug
can lead to the development of a bacterial population re-
sistant to that drug. Likewise, the addition of a single drug
to a failing anti-TB regimen can lead to resistance to that
drug. When two or more drugs to which there is suscepti-
bility are used simultaneously, each helps prevent the
emergence of tubercle bacilli resistant to the others.
The initial phase of treatment is crucial for preventing
the emergence of drug resistance and determining the ul-
timate outcome of the regimen. Four drugs — isoniazid, rifampin, pyrazinamide, and either
ethambutol or streptomycin — should be included in the initial treatment regimen until the
results of drug susceptibility tests are available. Each of the drugs in the initial regimen
plays an important role. Isoniazid and rifampin allow for short-course regimens with high
cure rates. Pyrazinamide has potent sterilizing activity which allows further shortening of
the regimen from 9 to 6 months. Ethambutol (or streptomycin) is added to prevent the
emergence of drug resistance when primary isoniazid resistance is possible. In the rare
circumstance where the disease-causing strain is known to be drug-sensitive or where the
likelihood of drug resistance is low (i.e., less than 4% primary resistance to isoniazid in the
community and the patient has had no previous treatment with TB drugs, is not from a
country with a high prevalence of drug resistance, and has no known exposure to a patient
with drug-resistant disease), three drugs (isoniazid, rifampin, and pyrazinamide) may be
adequate for the initial regimen.
There are several options for daily and intermittent therapy, but the aim of treatment should
be to provide the safest and most effective therapy in the shortest period of time. Given
adequate treatment, almost all patients will become bacteriologically negative, recover, and
remain well.
For each patient with newly diagnosed TB, a specific treatment and monitoring plan should
be developed in collaboration with the local health department within 1 week of the pre-
sumptive diagnosis. This plan should include a description of the treatment regimen, the
methods of assessing and ensuring adherence to the anti-TB regimen, and the methods of
monitoring for adverse reactions.
SLIDE 67
Basic Principles of Treatment
➤ Provide safest, most effective therapy in shortest
time
➤ Multiple drugs to which the organisms are
susceptible
➤ Never add single drug to failing regimen
➤ Ensure adherence to therapy
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Adherence
Nonadherence to TB treatment is a major problem in TB
control. Of cases reported in the United States for 1994,
14% of patients who were started on treatment had not
completed a full course by 1998.1 Inadequate treatment
can lead to relapse, continued transmission, and the de-
velopment of drug resistance.
Most health departments have public health nurses or com-
munity outreach workers who can work with patients and
clinicians to help patients adhere to a prescribed regimen.
Whenever possible, a worker who has the same cultural
and linguistic background as the patient should be assigned
to help develop an individualized treatment adherence
plan.
Patient Education
All patients should be educated about TB, the dosing of medications, the possible adverse
reactions of the medications, and the importance of taking their medication. Health care
workers must take the time to explain clearly to patients when the medication should be
taken, how much, and how often, especially if the patient is not receiving directly observed
therapy (DOT). Written instructions should also be provided.
Case Management
One strategy that may be used to ensure that patients com-
plete TB treatment is case management. There are three
elements of case management: assignment of responsi-
bility, systematic regular review, and plans to address bar-
riers to adherence. In case management, a health depart-
ment employee (case manager) is assigned primary re-
sponsibility for the management of specific patients and
is held accountable for ensuring that each of those pa-
tients is educated about TB and its treatment, that therapy
is continuous, and that contacts are examined. Some spe-
cific responsibilities may be assigned to other persons (e.g.,
clinic supervisors, outreach workers, health educators, and
social workers).
Directly Observed Therapy
A component of case management that helps to ensure that patients adhere to therapy is
directly observed therapy (DOT). DOT means that a health care worker or another desig-
nated person watches the patient swallow each dose of TB medication. DOT ensures an
accurate account of how much medication the patient really took. DOT should be consid-
ered for all patients because clinicians are often inaccurate in predicting which patients will
adhere to medication regimens on their own.2  However, it takes good case management in
concert with DOT to really make DOT programs effective.
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treatment
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In many areas, patients are routinely given DOT.3 DOT
has been shown to be cost-effective when intermittent regi-
mens are used.4,5  Furthermore, DOT can significantly re-
duce the frequency of the development of drug resistance
and of treatment failure or relapse after the end of treat-
ment.6,7 Nearly all the treatment regimens for drug-sus-
ceptible TB can be given intermittently if they are directly
observed; using intermittent regimens reduces the total
number of doses a patient must take, as well as the total
number of encounters with the health care provider or
outreach worker, making these regimens more cost-ef-
fective. Multidrug-resistant TB (MDR TB) should always
be treated with a daily regimen and under direct observa-
tion. There are no intermittent regimens for treatment of
MDR TB.
It is important that DOT be carried out at times and in locations that are as convenient as
possible for the individual patient. Therapy may be directly observed in a medical office or
clinic setting, but can also be observed by an outreach worker in the field (i.e., the patient’s
home, place of employment, school, or other mutually agreed-upon place). In some situa-
tions, staff of correctional facilities or of drug treatment programs, home health care work-
ers, maternal and child health staff, or designated community members may provide DOT.
Incentives and enablers should be used to enhance adherence to therapy. This may be as
simple as offering a cup of coffee and talking with a patient who is waiting in the clinic or as
complex as providing food and housing for a homeless patient. Establishing a relationship
with the patient and addressing barriers to adherence is the core of a successful DOT
program.
Health care professionals, including private practitioners, who note that a particular TB
patient has demonstrated the inability or unwillingness to adhere to a prescribed treatment
regimen should consult the health department. The TB control program in the health depart-
ment should assist in evaluating the patient for causes of nonadherence and should provide
additional services, such as the services of outreach workers, to enable the patient to com-
plete the recommended therapy. If these efforts are unsuccessful, the health department
should take appropriate action, such as seeking court-ordered DOT or, if all other measures
fail, the detention of a patient who is unwilling or unable to complete treatment and who is
infectious, at risk of becoming infectious, or at risk for drug-resistant TB.
Self-Administered Therapy
When therapy is self-administered, the use of fixed-dose combination capsules or tablets
may enhance patient adherence and reduce the risk of inappropriate monotherapy. There-
fore, it may prevent the development of acquired drug resistance. For this reason, the use of
such fixed-dose combinations is strongly encouraged for adults prescribed a self-adminis-
tered regimen. In the United States, the Food and Drug Administration has licensed fixed-
dose combinations of isoniazid and rifampin (Rifamate) and of isoniazid, rifampin, and
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➤ Health care worker watches patient swallow each
dose of medication
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pyrazinamide (Rifater). Clinicians should become familiar with the management of TB
using these fixed-dose combination drugs. In addition, incentives and enablers should be
used to enhance adherence to therapy.
Patients should be asked routinely about adherence at follow-up visits. Pill counts should be
taken routinely, and urine tests can be used periodically to check for the presence of drug
metabolites. In addition, the response to treatment (bacteriologic conversion to negative)
should be monitored closely for all patients. If the patient’s sputum remains positive after 2
months of treatment, the patient should be reevaluated and DOT should be considered for
the remainder of treatment.
Regimens
(See tables 3 - 7, pp. 116-124)
Pulmonary TB
The duration of therapy depends on the drugs used, the drug susceptibility test results, and
the patient’s response to therapy. All TB drugs should be given once daily rather than in
divided doses. Most patients with previously untreated pulmonary TB can be treated with
either a 6-month or a 9-month regimen, although the 6-month regimen is preferred.8 Both
the 6-month and 9-month regimens are referred to as short-course regimens. All regimens
of 9 months or less must contain isoniazid and rifampin; all 6-month regimens must contain
isoniazid, rifampin, and, initially, pyrazinamide.
For adults with smear- or culture-positive pulmonary TB, the initial phase of a 6-month
regimen should consist of a 2-month period of isoniazid, rifampin, and pyrazinamide. Etham-
butol or streptomycin should also be included in the initial regimen until the results of drug
susceptibility studies confirm isoniazid and rifampin susceptibility.
The initial use of a four-drug regimen is recommended to prevent the development of
multidrug-resistant TB in areas where the prevalence of primary isoniazid resistance is 4%
or higher. If susceptibility to isoniazid and rifampin is demonstrated, the second phase of
treatment should consist of isoniazid and rifampin for an additional 4 months.
If DOT is used, medications may be dosed intermittently.
Several options exist for 6-month, intermittent regimens:
• Four-drug therapy, administered daily for 8
weeks, may be followed by therapy with isoniazid
and rifampin given two or three times a week for
16 weeks (if susceptibility to isoniazid and
rifampin is demonstrated);9
• Four-drug therapy, administered daily for 2 weeks
and then two times a week for 6 weeks, may be
followed by therapy with isoniazid and rifampin
given two times a week for 16 weeks (if suscep-
tibility to isoniazid and rifampin is demon-
strated);9
Treatment of TB for HIV-Negative
Persons




➤ Ethambutol (EMB) or streptomycin (SM)
➤ Adjust regimen when drug susceptibility results
are known
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• Four-drug therapy may be administered three times a week throughout the 6-month
treatment period. All four drugs should be continued throughout the course of treat-
ment in this regimen.10
When isoniazid, pyrazinamide, and ethambutol or streptomycin are given two or three times
a week instead of every day, their dosages must be increased. However, the dose of rifampin
is the same whether the drug is given daily or intermittently.
Alternatively, a 9-month regimen of isoniazid and rifampin is acceptable for persons who
cannot or should not take pyrazinamide (e.g., pregnant women). Again, streptomycin
(except in pregnant women) or ethambutol should be included initially unless there is little
possibility of drug resistance (patient has no individual risk factors for drug resistance and
resides in an area where the prevalence of isoniazid-resistant TB < 4%). If susceptibility to
isoniazid and rifampin is demonstrated, isoniazid and rifampin may be given twice weekly
after an initial 4-8 weeks of daily treatment.11
For adults with smear- and culture-negative pulmonary TB (i.e., TB diagnosed only clini-
cally), a 4-month regimen of isoniazid and rifampin combined with pyrazinamide for the
first 2 months, may be used when drug resistance is unlikely.12,13
HIV-Positive Persons
(See table 4, pp. 118-119)
Management of HIV-related TB disease is complex, and
the clinical and public health consequences associated
with the failure of treatment are serious. Whenever pos-
sible, the care for HIV-related TB should be provided by
or in consultation with experts in the management of both
TB and HIV disease.
Published guidelines recommend the use of antiretroviral
therapy for patients infected with HIV.14 Widely used
antiretroviral drugs available in the United States include
the protease inhibitors (saquinavir, indinavir, ritonavir,
efavirenz, and nelfinavir) and the nonnucleoside reverse
transcriptase inhibitors (NNRTIs) (nevirapine and
delavirdine). However, these inhibitors interact with rifamycin derivatives, such as rifampin
and rifabutin, which are used to treat and prevent the mycobacterial infections commonly
observed in HIV-positive patients. Of the rifamycins, rifampin has the most potent interac-
tions; rifabutin has substantially fewer interactions. Because the most recent recommenda-
tions for the use of antiretroviral therapy strongly advise against interruptions of therapy,16
and because non–rifampin-containing alternatives for TB treatment are available, previous
antituberculosis therapy options that involved stopping antiretroviral therapy to allow the
use of rifampin are no longer recommended. The other class of antiretroviral agents avail-
able in the U.S., nucleoside reverse transcriptase inhibitors (NRTIs), which include
zidovudine, didanosine, zalcitabine, stavudine, lamivudine, and abacavir, are not contrain-
dicated with the use of rifamycins and do not require dose adjustments.
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The use of rifampin to treat TB is not generally recommended for patients who
• Will start treatment with an antiretroviral regimen that includes a protease inhibitor
or an NNRTI at the same time they begin treatment for TB, or
• Have established HIV infection that is being maintained on such an antiretroviral
regimen when TB is newly diagnosed and needs to be treated.
Two TB treatment options are currently recommended for
these patients:
1. A rifabutin-based regimen
The initial phase of a 6-month TB regimen for
patients who are receiving therapy with protease
inhibitors or NNRTIs consists of isoniazid,
rifabutin, pyrazinamide, and ethambutol for the
first 2 months (8 weeks). The initial phase should
be followed by isoniazid and rifabutin to com-
plete 6 months if sensitivity to isoniazid and
rifampin has been documented. Treatment should
be prolonged to 9 months or longer for patients
with delayed response to therapy.
2. An alternative nonrifamycin regimen that
includes streptomycin
The initial phase of a 9-month TB regimen for
patients for whom the use of rifamycins is lim-
ited or contraindicated for any reason (e.g., intol-
erance to rifamycins, patient/clinician decision not
to combine antiretroviral therapy with rifabutin),
consists of a 2-month induction phase of isoniazid,
ethambutol, pyrazinamide, and streptomycin,
followed by isoniazid, pyrazinamide, and strep-
tomycin administered 2-3 times per week for 7
months (30 weeks). Every effort should be made
to continue the administration of streptomycin
for the total duration of treatment. If streptomy-
cin is not used for the recommended 9 months,
ethambutol should be added to the continuation
phase of the regimen and treatment duration
should be prolonged from 9 months (38 weeks) to 12 months (52 weeks).
A rifampin-based regimen continues to be recommended for the treatment of TB in HIV-
positive patients
• Who have not started antiretroviral therapy, and both the patient and the clinician
agree that it would be prudent to wait before starting such therapy, or
• For whom antiretroviral therapy with a protease inhibitor or NNRTI is not recom-
mended.
Treatment of TB for HIV-Positive
Persons (cont.)
RIF-based regimens generally recommended for persons
➤ Who have not started antiretroviral therapy
➤ For whom PIs or NNRTIs are not recommended





RIF may be used with some PIs and NNRTIs
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➤ An alternative nonrifamycin regimen includes
INH, EMB, PZA, and streptomycin (SM)
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The following treatment option is recommended for these patients:
• The initial phase of a 6-month regimen consists of isoniazid, rifampin, pyrazina-
mide, and ethambutol (or streptomycin) for the first 2 months (8 weeks), followed
by isoniazid and rifampin to complete 6 months. Isoniazid, rifampin, pyrazina-
mide, and ethambutol (or streptomycin) can be administered for the entire 6-month
treatment period (26 weeks). Treatment should be prolonged to 9 months or longer
for patients with delayed response to therapy.
However, new data indicate that rifampin can be used for the treatment of active TB disease
for patients whose antiretroviral regimen includes
• The NNRTI efavirenz and two nucleoside reverse transcriptase inhibitors (NRTIs);
• The protease inhibitor ritonavir and one or more NRTIs; or
• The combination of two protease inhibitors (ritonavir and either saquinavir hard-
gel capsule or saquinavir soft-gel capsule).
All patients should receive monthly clinical evaluations to monitor their response to treat-
ment and medication side effects. During the early phase of treatment, the interval between
these evaluations may be shorter (e.g., every 2 weeks).
DOT and other adherence-promoting strategies should be used for all patients with HIV-
related TB. Pyridoxine (vitamin B
6
) (25-50 mg daily or 50-100 mg twice weekly) should be
administered to all HIV-positive patients who are undergoing TB treatment with isoniazid
to reduce isoniazid-induced side effects in the central and peripheral nervous system.
Note: These recommendations are not intended to substitute for the judgment of an expert
physician.  As new antiretroviral agents or new data regarding existing agents result in
changes in therapeutic options and preferences for antiretroviral therapy, these changes in
turn may impact the recommendations for the prevention and treatment of TB for patients
coinfected with HIV.
Extrapulmonary TB
(See tables 3 - 7, pp. 116-124)
As a general rule, regimens that are adequate for treating
pulmonary TB in adults and children are also effective
for treating extrapulmonary disease. However, infants and
children who have miliary TB, bone and joint TB, or TB
meningitis should receive a minimum of 12 months of
therapy.
The use of adjunct therapies such as surgery and corti-
costeroids is more commonly required for extrapulmonary
TB than for pulmonary disease. Surgery may be neces-
sary to obtain specimens for diagnosis and to treat such
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➤ In most cases, treat with same regimens used for
pulmonary TB
Bone and Joint TB, Miliary TB, or
TB Meningitis in Children
➤ Treat for a minimum of 12 months
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processes as constrictive pericarditis and spinal cord compression from Pott’s disease. Cor-
ticosteroids have been shown to be beneficial in preventing cardiac constriction from tuber-
culous pericarditis15 and in decreasing the neurologic sequelae of all stages of TB meningi-
tis,16 especially when administered early in the course of disease.
In patients with extrapulmonary TB, the type of follow-up examinations should be deter-
mined by the site of the disease. Bacteriologic evaluation may be limited by the relative
inaccessibility of the site. Thus, the response to treatment must often be judged on the basis
of clinical and radiologic findings.
TB Treatment for HIV-Positive Patients with Extrapulmonary TB
The basic principles that support the treatment of pulmonary TB in HIV-positive patients
also apply to extrapulmonary forms of the disease. Most extrapulmonary forms of TB (in-
cluding TB meningitis, tuberculous lymphadenitis, pericardial TB, pleural TB, and dis-
seminated or miliary TB) are more common among persons with advanced-stage HIV dis-
ease than among patients with asymptomatic HIV infection. The drug regimens and treat-
ment durations that are recommended for treating pulmonary TB in HIV-positive adults and
children are also recommended for treating most patients with extrapulmonary disease.
However, for certain forms of extrapulmonary disease, such as meningioma, bone TB, and
joint TB, using a standard rifamycin-based regimen for at least 9 months is generally rec-
ommended.
Pregnant or Lactating Women
Pregnant women with TB must be given adequate therapy
as soon as TB is suspected. The preferred initial treat-
ment regimen is isoniazid, rifampin, and ethambutol
(ethambutol may be excluded if primary isoniazid resis-
tance is unlikely). Streptomycin should not be used be-
cause it has been shown to have harmful effects on the
fetus. In addition, pyrazinamide should not be used rou-
tinely because its effect on the fetus is unknown. Because
the 6-month treatment regimen cannot be used, a mini-
mum of 9 months of therapy should be given. To prevent
peripheral neuropathy, it is advisable to give pyridoxine
(vitamin B
6
) to pregnant women who are taking isoniazid.
The small concentrations of TB drugs in breast milk do
not have a toxic effect on nursing newborns, and breast-feeding should not be discouraged
for women undergoing anti-TB therapy. Similarly, drugs in breast milk should not be con-
sidered effective treatment for disease or infection in a nursing infant.
TB Treatment for HIV-Positive Pregnant Women
HIV-positive pregnant women who have a positive M. tuberculosis culture or who are sus-
pected of having TB disease should be treated without delay. Choices of TB treatment regi-
mens for HIV-positive pregnant women are those that include a rifamycin. Although the
routine use of pyrazinamide during pregnancy is not recommended in the United States
Pregnant Women
➤ 9-month regimen of INH, RIF, and EMB
➤ PZA and SM are contraindicated
➤ PZA not contraindicated in HIV-positive pregnant
women
Children
➤ In most cases, treat with same regimens used for
adults
Infants
➤ Treat as soon as diagnosis suspected
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because of inadequate teratogenicity data, the benefits of a TB treatment regimen that in-
cludes pyrazinamide for HIV-positive pregnant women outweigh the potential pyrazina-
mide-related risks to the fetus. Aminoglycosides (e.g, streptomycin, kanamycin, amikacin),
capreomycin, and fluroquinolones are contraindicated for all pregnant women because of
adverse effects on the fetus.
Children and Adolescents
(See tables 3 - 7, pp. 116-124)
Infants and children with TB should be treated with one of the regimens mentioned in the
section Pulmonary TB, pp. 69-72. In infants, TB is much more likely to disseminate; there-
fore, prompt and vigorous treatment should be started as soon as the diagnosis is suspected.
The specific intermittent regimens have not been studied in children. Ethambutol is gener-
ally not used for young children whose visual acuity cannot be monitored. If ethambutol
must be used to treat a young child (e.g., because of drug-resistant TB), the minimum dose
of this drug should be used.17
Sputum specimens collected from children are often inadequate. In these situations, it may
be necessary to rely on the results of cultures and susceptibility tests of specimens from the
adult source case to confirm the diagnosis in the child and to guide the choice of drugs.
When drug-resistant TB is suspected or isolates from a source case are not available, it may
be necessary to perform gastric aspiration or bronchoalveolar lavage, or obtain tissue samples
for diagnosis.
For children, bacteriologic examinations are also less useful for evaluating the response to
treatment than for adults; thus, clinical and radiographic examinations are more important
for children. Furthermore, the chest radiographs of children with hilar adenopathy may not
become normal for 2 to 3 years after treatment. It is not necessary for the chest radiograph
to be normal before discontinuing TB drugs once a full course of therapy is completed.
In general, extrapulmonary TB in children can be treated with the same regimens as pulmo-
nary TB. The exceptions are bone and joint disease, disseminated (miliary) disease, and
meningitis, for which a minimum for 12 months of therapy is recommended.
TB Treatment for HIV-Positive Children
In HIV-positive children, even in those who are too young to be evaluated for visual acuity
and red-green perception, ethambutol at a dosage of 15 mg/kg body weight should gener-
ally be included as part of the initial regimen, unless the infecting source patient is known to
have TB susceptible to isoniazid and rifampin. If drug susceptibility results are not avail-
able, a four-drug rifamycin-based regimen (e.g., isoniazid, rifamycin, pyrazinamide, and
ethambutol) for 2 months, followed by isoniazid and a rifamycin for 4 months, is recommended.
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Drug-Resistant TB
(See table 3, pp. 116-117)
A 6-month regimen of isoniazid, rifampin, pyrazinamide,
and either ethambutol or streptomycin has been demon-
strated to be effective for the treatment of TB resistant
only to isoniazid.18  When resistance to isoniazid is docu-
mented during the recommended initial four-drug therapy,
the regimen should be adjusted by discontinuing isoniazid
and continuing the other three drugs for the entire 6 months
of therapy. TB resistant only to isoniazid may also be
treated with rifampin and ethambutol for 12 months.19
When isoniazid resistance is documented in the 9-month
regimen without pyrazinamide, isoniazid should be dis-
continued. If ethambutol was included in the initial regi-
men, treatment with rifampin and ethambutol should be continued for a minimum of 12
months. If ethambutol was not included initially, susceptibility tests should be repeated,
isoniazid should be discontinued, and two other drugs, to which the isolate is susceptible
(e.g., ethambutol and streptomycin), should be added. The regimen can be adjusted when
the results of the susceptibility tests become available.
Multidrug-resistant TB (i.e., TB resistant to at least isoniazid and rifampin) presents diffi-
cult treatment problems. Treatment must be individualized and based on the patient’s medi-
cation history and susceptibility studies.
Unfortunately, adequate data are not available on the effectiveness of various regimens and
the necessary duration of treatment for patients with organisms resistant to both isoniazid
and rifampin. Moreover, many of these patients also have resistance to other first-line drugs
(e.g., ethambutol and streptomycin) when drug resistance is discovered. Because of the
poor outcome in such cases, it is preferable to give at least three new drugs to which the
organism is susceptible. This regimen should be continued until culture conversion is docu-
mented, followed by at least 12 months of two-drug therapy. Often, a total of 24 months of
therapy is given empirically. Some experts recommend that at least 18-24 months of three-
drug therapy be given after culture conversion.20 MDR TB should be treated using a daily
regimen under direct observation (DOT). Intermittent administration of medications is not
possible in treatment of MDR TB.
Clinicians who are unfamiliar with the treatment of drug-resistant TB should seek expert
consultation. Because second-line drugs can cause serious adverse reactions, patients tak-
ing these drugs should be monitored closely throughout the course of treatment. The role of
agents such as the quinolone derivatives and amikacin in the treatment of multidrug-resis-
tant disease is not well characterized, although these drugs are commonly being used in
such cases. Surgery may offer considerable benefit and a significantly improved cure rate
for patients who have multidrug-resistant TB if the bulk of disease can be resected.21 How-
ever, drug therapy is usually required to sterilize the remaining disease.
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HIV-Negative Persons
➤ Carefully supervise and manage treatment to
avoid development of MDR TB
➤ Discontinue INH and continue RIF, PZA, and
EMB or SM for the entire 6 months
➤ Or, treat with RIF and EMB for 12 months
HIV-Positive Persons
➤ Regimen should consist of a rifamycin, PZA, and
EMB
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TB Treatment for HIV-Positive Patients with Drug-Resistant TB
TB disease resistant to isoniazid only. The treatment regimen should generally consist of
a rifamycin (rifampin or rifabutin), pyrazinamide, and ethambutol for the duration of treat-
ment. Because the development of acquired rifamycin resistance would result in MDR TB,
clinicians should carefully supervise and manage TB treatment for these patients.
TB disease resistant to rifampin only. The 9-month treatment regimen should generally
consist of an initial 2-month phase of isoniazid, streptomycin, pyrazinamide, and ethambu-
tol. The second phase of treatment should consist of isoniazid, streptomycin, and pyrazina-
mide administered for 7 months. Because the development of acquired isoniazid resistance
would result in MDR TB, clinicians should carefully supervise and manage TB treatment
for these patients.
Multidrug-resistant TB (resistant to both isoniazid and
rifampin). These patients should be managed by or in
consultation with physicians experienced in the manage-
ment of MDR TB. Most drug regimens currently used to
treat MDR TB include an aminoglycoside (e.g., strepto-
mycin, kanamycin, amikacin) or capreomycin, and a
fluoroquinolone, along with other agents to which the
organism is sensitive. The recommended duration of treat-
ment for MDR TB in HIV-positive patients is 24 months
after culture conversion, and posttreatment follow-up vis-
its to monitor for TB relapse should be conducted every
4 months for 24 months. Because of the serious personal
and public health concerns associated with MDR TB,
health departments should always use DOT for these pa-
tients and take whatever steps are needed to ensure their
adherence to the treatment regimen.
Persons with Additional Medical Problems
A number of medical conditions may alter immune responsiveness and predispose a person
to TB. Such disorders include HIV infection, immunosuppressive therapy, hematologic or
reticuloendothelial malignancies, chronic renal failure, diabetes, and malnutrition. These
conditions may influence the outcome of therapy. Therapeutic decisions for the impaired
host must be individualized.
Patients with partial impairment of renal function should avoid streptomycin, kanamycin,
and capreomycin if possible. If renal function is severely impaired, reduced doses or in-
creased dosing intervals of other TB drugs may be necessary (see table 7, pp. 124). Mea-
surement of drug serum levels may be helpful in adjusting the dosage.
For patients who abuse alcohol or who have neuropsychiatric disorders, close supervision
— preferably using DOT — is necessary to ensure adherence and to monitor for adverse
reactions to medications.
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➤ Clinicians unfamiliar with treatment of MDR TB
should seek expert consultation
➤ Always use DOT to ensure adherence
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Monitoring
Adverse reactions to TB drugs are relatively rare, but in
some patients they may be severe. Clinicians who treat
TB should be familiar with the methods of monitoring
for adverse reactions and response to treatment. In some
situations (e.g., drug-resistant TB, pregnancy, HIV-posi-
tive patients), expert consultation may be required.
Adverse Reactions to First-Line TB Drugs
(See tables 5 [pp. 120-121] and 6 [pp. 122-123])
Adults treated for TB should have baseline measurements
of hepatic enzymes, bilirubin, and serum creatinine or
blood urea nitrogen, as well as a complete blood and plate-
let count (or estimate). Serum uric acid should be measured
if pyrazinamide is used, and a baseline examination of
visual acuity should be obtained for patients for whom
ethambutol is prescribed. Audiometry should be performed at the beginning of therapy for
patients for whom streptomycin is prescribed. The purpose of these baseline tests is to
detect any abnormality that would complicate therapy or require a modified regimen. For
children, only baseline vision tests are necessary unless a child has other medical condi-
tions that may complicate therapy.
Monitoring for adverse reactions to TB medications must be individualized. The type and
frequency of monitoring should depend on the drugs used in a given regimen and the patient’s
risk for adverse reactions ( e.g., age, alcohol use). At minimum, patients should be seen
monthly during therapy and questioned by medical personnel concerning adverse reactions,
even if no problems are apparent. Patients should be specifically instructed to look for symp-
toms associated with the most common reactions to the medications they are taking. They
should also be instructed to seek medical attention immediately should these symptoms
occur. If the symptoms suggest adverse reactions, appropriate laboratory testing should be
performed.
All patients receiving isoniazid, rifampin, or pyrazinamide should be instructed to stop
taking the medications and to immediately report any hepatitis-suggesting symptoms (nau-
sea, loss of appetite, vomiting, persistently dark urine, yellowish skin, malaise, unexplained
elevated temperature for more than 3 days, or abdominal tenderness).
Isoniazid. Peripheral neuropathy is associated with the use of isoniazid but is uncommon at
doses of 5 mg/kg. Persons with conditions in which neuropathy is common (e.g., diabetes,
uremia, alcoholism, malnutrition, HIV infection), as well as pregnant women and persons
with a seizure disorder, may be given pyridoxine (10–50 mg/day) with isoniazid. As little as
6 mg/day of pyridoxine has been shown to prevent isoniazid-associated neuropathy. 22,23 The
interaction of isoniazid and phenytoin increases the serum concentration of both drugs.
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➤ Monitor patients at least monthly
➤ Monitoring for adverse reactions must be
individualized
➤ Instruct patients to immediately report adverse
reactions
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When these drugs are given concomitantly, the serum level of phenytoin should be moni-
tored. (See Treatment of Latent TB Infection, p. 53).
Rifampin. Rifampin may accelerate the clearance of drugs metabolized by the liver. These
include methadone, coumarin derivatives, glucocorticoids, estrogens, oral hypoglycemic
agents, digitalis, anticonvulsants, ketoconazole, fluconazole, cyclosporine, and protease
inhibitors. For patients who are in a drug-treatment program, it may be necessary to in-
crease the methadone dose by as much as 50%.24  Rifampin may also reduce the efficacy of
oral contraceptives and contraceptive implants (e.g., Norplant) by accelerating estrogen
metabolism. Women using hormonal contraception and taking rifampin should supplement
the contraception or use an alternative birth control method (i.e., barrier methods). Patients
receiving rifampin should be monitored for possible manifestations of thrombocytopenia
(bleeding tendency, easy bruising, blood in urine) or flu-like symptoms. Protease inhibitors
and NNRTIs interact with rifamycin derivatives, such as rifampin and rifabutin. Of the
rifamycins, rifampin has the most potent interactions; rifabutin has substantially fewer in-
teractions.
Pyrazinamide. Hyperuricemia may occur in patients receiving pyrazinamide, but acute gout
is uncommon. Asymptomatic hyperuricemia is not an indication for discontinuing the drug.
Streptomycin. Ototoxicity and neprotoxicity may occur in patients receiving streptomycin.
Audiometry should be performed at periodic intervals during streptomycin therapy. If ver-
tigo, dizziness, or ataxia occur in patients taking streptomycin, the drug should be discon-
tinued immediately.
Ethambutol. Optic neuritis is the most frequent and serious adverse effect of ethambutol.
Baseline and monthly tests of visual acuity and color vision should be conducted.
Current literature and package inserts should be consulted for other possible drug
reactions.
Response to Treatment
For patients whose sputum cultures are positive before
treatment, the best way to measure the effectiveness of
therapy is to obtain specimens for culture at least monthly
until the cultures convert to negative.  Patients whose spu-
tum no longer contains M. tuberculosis after 2 months of
treatment should have at least one further sputum smear
and culture performed at the completion of therapy. Pa-
tients with multidrug-resistant TB should have cultures
performed monthly for the entire course of treatment.
Radiographic evaluations during treatment are of less im-
portance than sputum evaluation. However, a chest film
at completion of treatment provides a baseline for com-
parison with any future films.SLIDE  80
Monitoring Response to Treatment
➤ Monitor patients bacteriologically monthly until
cultures convert to negative
➤ After 3 months of therapy, if cultures are positive
or symptoms do not resolve, reevaluate for
➤ Potential drug-resistant disease
➤ Nonadherence to drug regimen
➤ If cultures do not convert to negative despite 3
months of therapy, consider initiating DOT
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Patients whose cultures have not become negative or whose symptoms do not resolve de-
spite 3 months of therapy should be reevaluated for potential drug-resistant disease, as well
as for potential failure to adhere to the regimen. If the patient is receiving self-administered
therapy, the remainder of treatment should be directly observed. While the results of drug
susceptibility testing are pending, the original drug regimen may be continued or may be
augmented by at least two drugs not given previously. Never add one drug at a time to a
failing regimen; this may cause further drug resistance. If drug susceptibility results show
resistance to any of the first-line drugs or if the patient remains symptomatic or smear or
culture positive after 3 months, a TB medical expert should be consulted.
In patients with negative sputum cultures before treatment, the major indicators of response
to therapy are the chest radiograph and the clinical evaluation. The intervals at which chest
radiography should be repeated depend on the clinical circumstances and the differential
diagnosis that is being considered, but usually no more than every 3 months. If the radio-
graph does not improve after the patient has received 3 months of treatment, the abnormal-
ity may be the result of either previous (not current) TB or another process.
Routine follow-up after therapy is not necessary for patients who have had a satisfactory
and prompt bacteriologic response to 6- or 9-month therapy with both isoniazid and rifampin.
Patients whose organisms were fully susceptible to the drugs being used should be instructed
to promptly report the development of any symptoms, particularly prolonged cough, fever,
or weight loss. For patients with organisms resistant to isoniazid or rifampin or both, fol-
low-up evaluation must be individualized.
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Study Questions
Answers to these questions can be found in the text.
1. Why should at least two drugs be used to treat TB disease?
2. What factors can lead to drug resistance?
3. Which four drugs are recommended for the initial treatment of TB for HIV-negative
persons?
4. Describe the treatment options for HIV-positive persons who are on an antiretroviral
regimen.
5. Describe the treatment options for HIV-positive persons who are not on an antiretroviral
regimen.
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6. What is case management?
7. What is directly observed therapy (DOT)? Why should it be used?
8. How often should patients be monitored for adverse reactions to TB medications?
9. How can clinicians determine whether a patient is responding to therapy?
82 Core Curriculum on Tuberculosis
Endnotes
1. Centers for Disease Control and Prevention. Program Management Reports. Unpub-
lished data.
2. Mushlin AI, Appel FA. Diagnosing potential noncompliance. Arch Intern Med
1977;137:318-321.
3. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States,
1998. August 1999.
4. Burman WJ, Dalton CB, Cohn DL, Butler JRG, Reves RR. A cost-effectiveness analy-
sis of directly observed therapy vs self-administered therapy for treatment of tubercu-
losis. Chest 1997;112:63-70.
5. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of
directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit
Care Med 1996;154:1013-1019.
6. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the
rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330(17);1179-
1184.
7. McDonald RJ, Memon AM, Reichman LB. Successful supervised ambulatory man-
agement of tuberculosis treatment failures. Ann Intern Med 1982;96:297-302.
8. Combs DL, O’Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy
trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern
Med 1990;112:397-406.
9. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy
for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed,
and cost-effective regimen. Ann Intern Med 1990;112:407-415.
10. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a
controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis.
Am Rev Respir Dis 1987;136:1339-1342.
11. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly
twice-weekly isoniazid and rifampin. Community physicians’ seven-year experience
with mainly outpatients. Am J Med 1984;77:233-242.
12. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Re-
search Council. A controlled trial of 3-month, 4-month, and 6-month regimens of che-
motherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Am
Rev Respir Dis 1989;139:871- 876.
83What the Clinician Should Know
13. Dutt AK, Moers D, Stead WW. Smear- and culture-negative pulmonary tuberculosis:
four-month short-course chemotherapy. Am Rev Respir Dis 1989;139:867- 870.
14. Centers for Disease Control and Prevention. Report of the NIH panel to define prin-
ciples of therapy of HIV infection and guidelines on the use of antiretroviral agents in
HIV-infected adults and adolescents. MMWR 1998;47(No. RR-5):1-63.
15. Strang JIG, Kakaza HHS, Gibson DG, et al. Controlled trial of prednisone as adjunct
in treatment of tuberculosis constrictive pericarditis in Trankei. Lancet 1987;2:1418-
1422.
16. Girgis NI, Farid Z, Kilpatrick ME, et al. Dexamethasone as an adjunct to treatment of
tuberculosis meningitis. Ped Infect Dis J 1991;10:179-183.
17. Trébucq A. Should ethambutol be recommended for routine treatment of tuberculosis
in children? A review of the literature. Int J Tuberc Lung Dis 1997;1:12-15.
18. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of
six-month and four-month regimens of chemotherapy in the treatment of pulmonary
tuberculosis. Am Rev Respir Dis 1979;119:579-85.
19. Zierski M. Prospects of retreatment of chronic resistant pulmonary tuberculosis pa-
tients: a critical review. Lung 1977;154:91- 102.
20. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med
1993;329(11):784-791.
21. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment
of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev
Respir Dis 1990;141:623-625.
22. Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid
toxicity in the therapy of pulmonary tuberculosis. II. An assessment of the prophylac-
tic effect of pyridoxine in low dosage. Bull WHO 1963;29:457-481.
23. Krishnamurthy DV, Selkon JB, Ramachandran K, et al. Effect of pyridoxine on vita-
min B
6
 concentrations and glutamic-oxaloacetic transaminase activity in whole blood
of tuberculous patients receiving high-dosage isoniazid. Bull WHO 1967;36:853-870.
24. Selwyn PA. Medical aspects of human immunodeficiency virus infection and its treat-
ment in injecting drug users. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance
Abuse: A Comprehensive Textbook. 2nd ed. Baltimore: Williams & Wilkins; 1992:744-
774.
84 Core Curriculum on Tuberculosis
References
American Academy of Pediatrics. Tuberculosis. In: Peter G, ed. 1997 Red Book: Report of
the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy
of Pediatrics; 1997:541-563.
American Thoracic Society and Centers for Disease Control and Prevention. Treatment of
tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med
1994;149:1359-1374.
American Thoracic Society and Centers for Disease Control and Prevention. Control of
tuberculosis in the United States. Am Rev Respir Dis 1992;146:1623-1633.
American Thoracic Society and Centers for Disease Control and Prevention. Diagnostic
standards and classification of tuberculosis in adults and children. Am J Respir Crit Care
Med. In press.
Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for
HIV-infected persons: revised recommendations. MMWR 1997;46(No. RR-15).
Centers for Disease Control and Prevention. A strategic plan for the elimination of tubercu-
losis from the United States MMWR 1989;38(Suppl No.S-3).
Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles,
opportunities, and a renewed commitment. MMWR 1999;48(No. RR-9).
Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among
patients infected with human immunodeficiency virus: principles of therapy and revised
recommendations. MMWR 1998;47(No. RR- 20).
Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the
use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-
infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibi-
tors. MMWR 2000;49(9):185-189.
Centers for Disease Control and Prevention. Essential components of a tuberculosis preven-
tion and control program. MMWR 1995;44(No. RR-11):1-16.
Centers for Disease Control and Prevention. Guidelines for preventing the transmission of
Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994;43(No. RR-13).
Centers for Disease Control and Prevention. Management of persons exposed to multidrug-
resistant tuberculosis. MMWR 1992;41(No. RR-11):59-71.
Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the preven-
tion of opportunistic infections in persons infected with human immunodeficiency virus.
MMWR 1999;48(No. RR-10):11-14.
85What the Clinician Should Know
Centers for Disease Control and Prevention. Recommendations for prevention and control
of tuberculosis among foreign-born persons. MMWR 1998; 47(No.RR-16).
Centers for Disease Control and Prevention. Reported Tuberculosis in the United States,
1998. August 1999.
Selected Bibliography
Abbott Laboratories. Norvir package insert. Chicago, Illinois: Abbott Laboratories, 1999.
Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and
rifampin in healthy volunteers [Abstract]. In: Program and abstracts of the 12th World AIDS
Conference, Geneva, Switzerland, 1998.
Bloch AB, Simone PM, McCray E, Castro KG. Preventing multidrug-resistant tuberculosis
(editorial). JAMA 1996;275(6):487-489.
Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the
United States. Arch Intern Med 1995;155:1595-1600.
Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis
therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med
1996;154:1034-1038.
Chaulk CP and Kazandjian VA. Directly observed therapy for treatment completion of pul-
monary tuberculosis. JAMA 1998;279:943-948.
Davidson PT. Managing tuberculosis during pregnancy. Lancet 1995;346:199-200.
Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculo-
sis: a clinical reappraisal of the literature. Clin Infect Dis 1997;25:872-887.
Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis -- we can’t
afford not to try it. N Engl J Med 1993;328(8):576-578.
Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis: Hail Britannia (and
friends)! Am Rev Respir Dis 1991;143:697-698.
Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy
in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med
1994;150:1499-1502.
Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow up of persons with HIV-1 -
and HIV-2 - associated pulmonary tuberculosis treated with short-course chemotherapy in
West Africa. AIDS 1995;9:1185-1191.
86 Core Curriculum on Tuberculosis
Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors
and their association with the acquisition of drug resistance. JAMA 1993;270(1):65-68.
Mitchison DA. Drug resistance in mycobacteria. British Med Bull 1984;40:84-90.
Mitchison DA. How drug resistance emerges as a result of poor compliance during short
course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-15.
Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculo-
sis treatment: predictors and consequences in New York City. Am J Med 1997;102:164-170.
Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin
Chest Med 1997;18:79-87.
Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in
patients with AIDS. Ann Pharmacother 1996;30:919-925.
Perriëns JH, St. Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected pa-
tients in Zaire. N Engl J Med 1995;332:779-784.
Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tu-
berculosis. Am J Respir Crit Care Med 1998;157:1881-1884.
Rubel AJ, Garro LC. Social and cultural factors in the successful control of tuberculosis.
Public Health Rep 1992;107:626-636.
Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment
of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl
J Med 1991;324:289-294.
Snider DE. Pregnancy and tuberculosis. Chest 1984;86S:10S-13S.
Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61:191-196.
Stead WW, Dutt AK. Tuberculosis in elderly persons. Annu Rev Med 1991;42:267-276.
Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient ad-
herence. Am Rev Respir Dis 1993;147:1311-1320.
Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of
human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med
1995;151:129-135.
Veldkamp AI, Hoetelmans MW, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables
combined therapy with rifampin and saquinavir. Clin Infect Dis 1999;29:1586.
Villarino ME, Geiter LJ, Simone PM. The multidrug-resistant tuberculosis challenge to
public health efforts to control tuberculosis. Public Health Rep 1992:107(6):616-625.
87What the Clinician Should Know
Summary.   The infectiousness of TB patients is directly related to the number
of tubercle bacilli that they expel into the air. Infectiousness usually declines
very rapidly after adequate therapy is started. The main goal of an infection
control program is to detect TB disease early and to isolate and promptly treat
persons who have TB. An infection control program should involve three types
of controls — administrative controls, engineering controls, and personal respi-
ratory protection — and should be based on a risk assessment of the setting
(inpatient and outpatient). Administrative controls (e.g., the prompt detection of
suspected cases, isolation of infectious patients, and appropriate treatment) com-
prise the primary strategy for infection control. Administrative controls also in-
clude training and education and TB screening for health care workers (HCWs).
In addition, three types of engineering controls may be used to prevent the trans-
mission of TB: ventilation, high-efficiency particulate air (HEPA) filtration, and
ultraviolet germicidal irradiation (UVGI).
In places where administrative and engineering controls may not fully protect
health care workers from infectious droplet nuclei, HCWs should use personal
respirators. Precautions to prevent airborne transmission are particularly impor-
tant in TB isolation rooms and during and immediately after procedures that
stimulate coughing (e.g., sputum collection, bronchoscopy, and aerosolized pen-
tamidine treatments).
Coordination with the health department is necessary in order to report all con-
firmed or suspected TB patients, conduct contact investigations, and plan for
follow-up care for patients known to have or suspected of having TB.
Objectives
After working through this chapter, you will be able to
• Explain when a TB patient can be considered noninfectious;
• List the three types of controls in an effective infection control program;
• Explain the purpose and the characteristics of a TB isolation room;
• Describe the circumstances when personal respirators should be used.
Chapter Eight
Infection Control in Health Care Settings
88 Core Curriculum on Tuberculosis
Infectiousness
Infectiousness is directly related to the number of tubercle
bacilli expelled into the air. In general, persons who have
or who are suspected of having pulmonary or laryngeal
TB should be considered infectious if they are
1. Coughing, are undergoing cough-inducing or
aerosol-generating procedures, or have sputum
smears containing acid-fast bacilli; and
2. Not receiving therapy, have just started therapy,
or have a poor clinical or bacteriologic response
to therapy.
Patients who have drug-susceptible TB are no longer con-
sidered infectious if they meet all the following criteria:
• They are on adequate therapy;
• They have had a significant clinical response to
therapy;
• They have had three consecutive negative spu-
tum smear results from sputum collected on
different days.
Persons with extrapulmonary TB are usually not infec-
tious. However, TB has been transmitted from a draining
skin or tissue abscess containing M. tuberculosis.1
Patients with TB disease should be closely monitored for
response to therapy. Smear examinations should be done
regularly (e.g., initially every 1 or 2 weeks). Persistent
infectiousness is usually due to the patient’s failure to take
medications as prescribed or to drug resistance. These
possibilities should be considered for any patient who does not clinically respond to therapy
within 2 to 3 weeks.
In patients with drug-resistant TB, infectiousness may last several weeks or even months. In
these patients, the response to treatment should be closely monitored, and for those in insti-
tutional settings, TB isolation should be maintained until infectiousness is ruled out. Con-
tinued isolation throughout hospitalization should be considered for patients with multidrug-
resistant TB because these patients are more likely to experience treatment failure or
relapse, which may prolong infectiousness.
SLIDE 82
Infectiousness
Patients should be considered infectious if they
➤ Are coughing
➤ Are undergoing cough-inducing or aerosol-
generating procedures, or
➤ Have sputum smears positive for acid-fast bacilli
and they
➤ Are not receiving therapy
➤ Have just started therapy, or
➤ Have poor clinical response to therapy
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Infectiousness (cont.)
Patients no longer considered infectious if they meet
all of these criteria:
➤ Are on adequate therapy
➤ Have had a significant clinical response to
therapy, and
➤ Have had 3 consecutive negative sputum smear
results
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Developing an Infection Control Program
An effective TB infection control program requires the early detection, isolation, and treat-
ment of persons with infectious TB. TB infection control measures should be based on a
careful assessment of risk for transmission of TB in the facility or setting. The primary
emphasis of the infection control plan should be on achieving these three goals through a
hierarchy of control measures, including
• The use of administrative controls to reduce the
risk of exposure to persons with infectious TB;
• The use of engineering controls to prevent the
spread and reduce the concentration of infectious
droplet nuclei in the air;
• The use of personal respiratory protection in ar-
eas where there is an increased risk of exposure
to M. tuberculosis, such as in TB isolation rooms.
Administrative Controls
The first level of the hierarchy, the use of administrative
controls, is the primary strategy for infection control.
Administrative controls are measures intended primarily
to reduce the risk of exposing uninfected persons to per-
sons who have infectious TB. These measures include
• Developing and implementing effective written
policies and protocols to ensure the rapid identi-
fication, isolation, diagnostic evaluation, and treat-
ment of persons likely to have TB;
• Implementing effective work practices among
health care workers (HCWs);
• Educating, training, and counseling HCWs about
TB;
• Screening HCWs for TB infection and disease.
All health care facilities or settings must have guidelines
for the prompt detection of suspected TB cases. These
guidelines should include assigning supervisory responsibility for TB control.
In general, clinicians should suspect TB in any patient who has a persistent cough (i.e., a
cough lasting for ≥ 3 weeks), bloody sputum, night sweats, fever, weight loss, or loss of
appetite. The index of suspicion should be very high in areas or among groups of patients in
which the prevalence of TB is high. In ambulatory and inpatient settings, designated per-
sonnel should develop a protocol for the early detection of persons with infectious TB,
basing it on the prevalence and characteristics of TB in the population served.
Infection Control Measures
➤ Administrative controls to reduce risk of
exposure
➤ Engineering controls to prevent spread and
reduce concentration of droplet nuclei
➤ Personal respiratory protection in areas where
increased risk of exposure
Administrative Controls
Reduce risk of exposing uninfected persons to infectious
disease:






➤ Implement effective work practices among HCWs
➤ Educate, train, and counsel HCWs about TB
➤ Test HCWs for TB infection and disease
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Risk Assessment
TB infection-control measures should be based on the assessment of the risk for transmis-
sion of TB in that particular setting. Classification of risk for a facility, for a specific area,
and for a specific occupational group should be based on
• The profile of TB in the community;
• The number of infectious TB patients admitted
to the area or ward, or the estimated number of
infectious TB patients to whom HCWs in an
occupational group may be exposed; and
• The results of analysis of HCW skin test con-
versions (where applicable) and possible per-
son-to-person transmission of M. tuberculosis.
All TB infection-control programs should include peri-
odic reassessments of risk. The frequency of repeat risk
assessments should be based on the results of the most
recent risk assessment.
Regardless of risk level, the management of patients with
known or suspected infectious TB should not vary. However, the index of suspicion for
infectious TB among patients, the frequency of HCW skin testing programs, the number of
TB isolation rooms, and other factors will depend on whether the risk for transmission of
M. tuberculosis in the facility, area, or occupational group is high, intermediate, low, very
low, or minimal.
Inpatient Settings. The risk assessment should be conducted for the entire facility and for
specific areas within the facility (e.g., medical, TB, pulmonary, or HIV wards; HIV, infec-
tious disease, or pulmonary clinics; and emergency departments or other areas where TB
patients might receive care or where cough-inducing procedures are performed). In addi-
tion, risk assessments should be conducted for groups of HCWs who work throughout the
facility rather than in a specific area (e.g., respiratory therapists; bronchoscopists; environ-
mental services, dietary, and maintenance personnel; and students, interns, residents, and
fellows).
Outpatient Settings. In outpatient settings, such as medical offices, a risk assessment should
be conducted periodically and TB control policies should be developed.
Managing Suspected and Confirmed Cases of TB
Inpatient Settings. In hospitals and other inpatient settings, such as hospices and emer-
gency rooms, patients known to have TB or suspected of having TB should be placed in a
TB isolation room right away. All TB isolation rooms must have negative pressure relative
to other parts of the facility (air flow from the corridors into the isolation room) and must be
checked daily while in use to ensure proper air flow.
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Administrative Controls (cont.)
Perform risk assessment and classification of facility
based on
➤ Profile of TB in community
➤ Number of infectious TB patients admitted
➤ Analysis of HCW skin test conversions
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Patients who are placed in isolation rooms should be educated about the transmission of
TB, the reasons for isolation, and the importance of staying in their rooms. Every effort
should be made to help the patient follow the isolation policy — including the use of incen-
tives, such as providing telephones or televisions or allowing special dietary requests. As
few persons as possible should enter the TB isolation room, and anyone entering the room
should wear respiratory protection (see Personal Respiratory Protection, p. 93).
If patients who may have infectious TB must be transported outside their isolation rooms
for medically essential procedures that cannot be performed in the isolation rooms, they
should wear surgical masks that cover the mouth and nose during transport. Persons trans-
porting the patients do not need to wear respiratory protection outside TB isolation rooms.
Procedures for these patients should be scheduled at times when they can be performed
rapidly and when waiting areas are less crowded.
Because TB is transmitted through the air rather than by fomites or direct contact, the ster-
ilization of personal items or eating utensils and the cleaning of walls are unnecessary.
Outpatient Settings. In an outpatient setting (e.g, medical offices, clinics), patients who
have signs or symptoms of TB should be moved to an area away from other patients (pref-
erably into a TB isolation room) and promptly given a diagnostic evaluation. These patients
should be given a surgical mask and instructed to keep it on. They should also be given
tissues and asked to cover the nose and mouth when coughing or sneezing to contain droplet
nuclei before they are expelled into the air.
When EMS personnel must transport patients who are suspected or confirmed cases of TB,
a surgical mask should be placed over the patient’s nose and mouth.
After a thorough and timely diagnostic evaluation (see Diagnosis of TB, p. 39), patients in
whom TB has been confirmed or is suspected should start appropriate therapy at once. TB
should be considered in HIV-positive patients with undiagnosed pulmonary disease. If TB
is suspected, appropriate precautions to prevent airborne transmission should be taken un-
less infectious TB is ruled out.
TB Skin Testing and Prevention Program for Health Care Workers
The risk assessment should identify which HCWs have the potential for exposure to TB and
the frequency with which the exposure may occur. This information can then be used to
determine which HCWs to include in the skin-testing program and the frequency with which
they should be tested. Health care workers, including home health nurses and emergency
medical technicians, should be included in a TB testing and prevention program if the risk
assessment indicates that they are at risk for exposure. This means tuberculin skin testing
for HCWS upon employment and at repeated intervals determined by their risk of exposure
thereafter. Any worker who develops symptoms of TB disease or whose tuberculin skin test
result converts to positive should be evaluated promptly.  In addition, all health care workers
should be educated about the basic concepts of TB transmission and pathogenesis, includ-
ing information concerning the difference between latent TB infection and active TB dis-
ease, infection control practices, the signs and symptoms of TB, and the importance of
participating in the employee skin testing program.
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Discharge Planning
Health care facilities should work closely with the health department to report all confirmed
or suspected cases of TB, to ensure that contact investigations are carried out for all cases,
and to develop an appropriate discharge plan, including arrangements for DOT and follow-
up care, for TB patients or persons suspected of having TB. Patients who are suspected of
having infectious TB may be discharged to their home after starting TB therapy, even though
they may still be infectious. It is important to note that after treatment has started, persons
who have TB are less likely to transmit the disease to members of their household. How-
ever, before the patient is discharged to home, clinicians and discharge planners should
consider whether any household members were previously exposed or are at very high risk
for TB disease if infected (e.g., HIV-positive or otherwise severely immunocompromised
persons or children ≤4 years of age). If the household does include such persons, arrange-
ments should be made to prevent them from being exposed to the TB patient until a determi-
nation has been made that the patient is noninfectious.
Engineering Controls
The second level of the hierarchy is the use of engineer-
ing controls to prevent the spread and reduce the concen-
tration of infectious droplet nuclei. Engineering controls
are based primarily on the use of adequate ventilation
systems; these may be supplemented with high-efficiency
particulate air (HEPA) filtration and ultraviolet germicidal
irradiation (UVGI) in high-risk areas. These strategies are
designed to reduce the concentration of infectious drop-
let nuclei in the air, prevent the dissemination of droplet
nuclei throughout the facility, or render droplet nuclei non-
infectious by killing the tubercle bacilli they contain.
Inpatient Settings. In isolation rooms, ventilation sys-
tems are necessary to maintain negative pressure and to exhaust the air properly. Isolation
rooms should be monitored daily when in use to ensure the negative pressure is maintained.
Isolation room doors should be kept closed, except when patients or personnel must enter or
exit the room, in order to maintain negative pressure. Ventilation systems can also be de-
signed to minimize the spread of TB in other areas of the health care facility.
HEPA filters can be used in ventilation systems to remove droplet nuclei from the air. These
filters can be installed in ventilation ducts to filter air for recirculation into the same room or
recirculation to other areas of a facility. The effectiveness of portable HEPA filtration units
has not been adequately evaluated. All HEPA filters must be carefully installed and meticu-
lously maintained to ensure adequate function.
UVGI, or ultraviolet lighting, may kill M. tuberculosis contained in droplet nuclei. Because
exposure to ultraviolet light can be harmful to the skin and eyes, the lamps must be installed
in the upper part of rooms or corridors or placed in exhaust vents.
Outpatients settings. In outpatient settings, such as medical offices, that provide care to
populations at high risk for TB, the use of engineering controls may be appropriate.
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Engineering Controls
To prevent spread and reduce concentration of
infectious droplet nuclei
➤ Use ventilation systems in TB isolation rooms
➤ Use HEPA filtration and ultraviolet irradiation with
other infection control measures
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Personal Respiratory Protection
The third level of the hierarchy is the use of personal res-
piratory protection. In some settings — for example, TB
isolation rooms and rooms where cough-inducing proce-
dures are done — administrative and engineering con-
trols may not fully protect health care workers from in-
fectious droplet nuclei. Health care workers should use
personal (particulate) respirators in these settings.  The
Occupational Safety and Health Administration (OSHA)
requires the use of certified respirators when respiratory
protection is needed. Only particulate respirators that have
been certified by the National Institute for Occupational
Safety and Health (NOSH) should be worn for TB pro-
tection. A respiratory protection program that teaches
health care workers how and when to use personal respirators should be included in all
infection control programs.
Some people confuse surgical masks and personal (particulate) respirators. Surgical masks
are designed to prevent the respiratory secretions of the person wearing the mask from
entering the air.  Particulate respirators are designed to filter the air before it is inhaled by
the person wearing the respirator. Patients suspected of having or known to have TB should
never wear a respirator that has an exhalation valve, because this type of respirator does not
prevent expulsion of droplet nuclei into the air.
Inpatient Settings. Precautions to prevent the airborne transmission of tubercle bacilli are
particularly important during and immediately after procedures that stimulate coughing
(e.g., sputum collection, sputum induction, bronchoscopy, and aerosolized pentamidine treat-
ments) by persons at risk for TB. Persons who carry out these procedures should wear
personal respirators, and the procedures should be done in rooms or booths with negative
air pressure in relation to adjacent rooms or hallways. The air from these rooms should be
exhausted directly to the outside and away from intake sources.
Outpatient Settings. HCWs who work in outpatient settings, such as medical and dental
offices, should use personal respiratory protection when working with patients who have, or
who are strongly suspected of having, infectious TB. This includes using personal respira-
tors when visiting the home of an infectious TB patient.
EMS personnel should wear respiratory protection when transporting patients suspected or
confirmed to have TB. If feasible, the windows of the vehicle should be kept open. The
heating and air-conditioning system should be set on a nonrecirculating cycle.
Personal Respiratory Protection
Use in areas where increased risk of exposure:
➤ TB isolation rooms
➤ Rooms where cough-inducing procedures are
done
➤ Homes of infectious TB patients
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Study Questions
Answers to these questions can be found in the text.
1. When can a TB patient be considered noninfectious?
2. What is the main goal of an infection control program?
3. What are the three types of controls in an effective infection control program?
4. What are the important characteristics of a TB isolation room?
5. What are the three types of engineering controls?
6. When should personal respirators be used?
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Summary.  BCG vaccination is not generally recommended in the United
States because of the low risk of infection with M. tuberculosis, the vari-
able effectiveness of the BCG vaccine against pulmonary TB, and the
vaccine’s interference with the ability to determine tuberculin reactivity. In
the United States, the use of BCG vaccination as a TB prevention strategy
is reserved for selected persons who meet specific criteria. BCG vaccina-
tion should be considered for infants and children who reside in settings in
which the likelihood of M. tuberculosis transmission and subsequent infec-
tion is high, provided no other measures can be implemented (e.g., remov-
ing the child from the source of infection). In addition, BCG vaccination
may be considered for health care workers who are employed in settings in
which the likelihood of transmission and subsequent infection with M. tu-
berculosis strains resistant to isoniazid and rifampin is high, provided com-
prehensive TB infection-control precautions have been implemented in the
workplace and have not been successful. BCG vaccination is not recom-
mended for children and adults who are infected with HIV because of the
potential adverse reactions associated with the use of the vaccine in these
persons. A diagnosis of M. tuberculosis infection and the use of treatment
for infection should be considered for any BCG-vaccinated person who
has a positive tuberculin skin test, especially if there is a likelihood of prior
exposure to M. tuberculosis.
Objectives
After working through this chapter, you will be able to
• Explain how reactions to the tuberculin skin test are interpreted for BCG-
vaccinated persons;
• Explain when BCG vaccination should be considered for an infant or child;
• Explain when BCG vaccination should be considered for health care workers.
Recommendations for the Use of BCG Vaccine
The use of BCG vaccination as a TB prevention strategy in the United States is limited
because its effectiveness in preventing infectious forms of TB is uncertain. In 1993 and
1994, two meta-analyses of the published results of BCG vaccine clinical trials and case-
control studies confirmed that the protective efficacy of BCG for preventing serious forms
of TB in children is high (i.e., >80%).1, 2  These analyses, however, did not clarify the protec-
tive efficacy of BCG for preventing pulmonary TB in adolescents and adults; this protective
Chapter Nine
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efficacy is variable, from 0% to 80%.3 Furthermore, BCG immunization may cause a posi-
tive reaction to the tuberculin skin test. Thus, it may complicate decisions about prescribing
treatment for infection for BCG-vaccinated persons who have a positive skin-test result.
CDC guidelines do not recommend including BCG vac-
cination in immunization programs or TB control pro-
grams. BCG vaccine should be considered only for se-
lected persons who meet specific criteria. These criteria
are seldom met and therefore the use of the BCG vacci-
nation should be undertaken only after consultation with
local health authorities and experts in the management of
TB. First, BCG vaccine should be considered for an in-
fant or child who has a negative tuberculin skin-test re-
sult if the following circumstances are present:
• The child is exposed continually to an untreated
or ineffectively treated patient who has infec-
tious pulmonary TB, and the child cannot be
separated from the presence of the infectious
patient or given long-term primary treatment for
infection;
 or
• The child is exposed continually to a patient
who has infectious pulmonary TB caused by
M. tuberculosis strains resistant to isoniazid and
rifampin, and the child cannot be separated from
the presence of the infectious patient.
Second, BCG vaccination of health care workers should
be considered on an individual basis in settings in which
• A high percentage of TB patients are infected
with M. tuberculosis strains resistant to both
isoniazid and rifampin;
• Transmission of such drug-resistant M. tuber-
culosis strains to health care workers and sub-
sequent infection are likely; and
• Comprehensive TB infection-control precau-





➤ Not recommended in immunization programs or
TB control programs in the U.S.





Considered for an infant or child with negative skin-
test result who
➤ Is continually exposed to untreated or
ineffectively treated patient
➤ Will be continually exposed to multidrug-resistant
TB
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Vaccination with BCG should not be required for em-
ployment or for assignment of health care workers in spe-
cific work areas. Health care workers considered for BCG
vaccination should be counseled regarding the risks and
benefits associated with both BCG vaccination and TB
preventive therapy.
BCG is contraindicated in persons who have an impaired
immune response (e.g., persons who have HIV infection,
congenital immunodeficiency, leukemia, lymphoma, or
generalized malignancy) or who are immunosuppressed
because of high-dose steroid therapy, alkylating agents,
antimetabolites, or radiation therapy. HIV infection should
be ruled out before BCG vaccine is administered to per-
sons in groups at high risk for HIV infection. It is also
prudent to avoid giving BCG vaccination to pregnant




with a History of BCG
Vaccination
Many foreign countries still use BCG as part of their TB
control programs, especially for infants. In persons vac-
cinated with BCG, sensitivity to tuberculin is highly vari-
able, depending upon the strain of BCG used and the group
vaccinated. The presence or size of a postvaccination tuberculin skin-test reaction does not
predict whether BCG will provide any protection against TB disease. Furthermore, the size
of a tuberculin skin-test reaction in a BCG-vaccinated person is not a factor in determining
whether the reaction is caused by M. tuberculosis infection or by the prior BCG vaccination.
Tuberculin skin testing is not contraindicated for persons who have been vaccinated with
BCG, and the skin-test results of such persons are used to support or exclude the diagnosis
of M. tuberculosis infection. The booster phenomenon may occur among persons who have
had a prior BCG vaccination (see Two-Step Testing, p 32). A diagnosis of M. tuberculosis
infection and the use of treatment for infection should be considered for any BCG-vacci-
nated person who has a tuberculin skin-test reaction of ≥10 mm of induration, especially if
any of the following circumstances are present:
• The vaccinated person is a contact of another person who has infectious TB, par-
ticularly if the infectious person has transmitted M. tuberculosis to others;
• The vaccinated person was born or has resided in a country in which the prevalence
of TB is high; or
Recommendations for BCG
Vaccination (cont.)
HCWs considered on individual basis in settings in
which
➤ High percentage of MDR TB patients has been
found
➤ Transmission of drug-resistant TB strains and
subsequent infection are likely, and
➤ Comprehensive TB infection-control precautions
implemented and not successful
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➤ Receiving high-dose steroid therapy
➤ Receiving alkylating agents
➤ Receiving antimetabolites
➤ Receiving radiation therapy
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• The vaccinated person is exposed continually
to populations in which the prevalence of TB is
high (e.g., some health care workers, employ-
ees and volunteers at homeless shelters, and
workers at drug-treatment centers).
Treatment for infection should be considered for BCG-
vaccinated persons who are infected with HIV and who
are at risk for M. tuberculosis infection if they have a
tuberculin skin-test reaction of ≥5 mm induration. Be-
cause HIV-infected persons may be anergic (i.e., may not
react to tuberculin because of immunosuppression), iso-
niazid treatment for infection should be considered for
these persons if they have a history of contact with an-
other person who has infectious TB, regardless of the fact
that they may be nonreactive to tuberculin.
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BCG Vaccination and Tuberculin
Skin Testing
➤ Tuberculin skin testing not contraindicated for BCG-
vaccinated persons
➤ LTBI diagnosis and treatment for LTBI considered for
any BCG-vaccinated person whose skin test reaction is
≥10 mm, if any of these circumstances are present:
➤ Was contact of another person with infectious TB
➤ Was born or has resided in a high TB prevalence
country
➤ Is continually exposed to populations where TB
prevalence is high
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Study Questions
Answers to these questions can be found in the text.
1. What is the current recommendation concerning BCG vaccination for most persons in
the United States?
2. Under what circumstances should BCG vaccination be considered in the United States?
3. When is BCG vaccination contraindicated?
4. When should a diagnosis of TB infection be considered in a BCG-vaccinated person?
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Summary. State and local health departments have the primary responsi-
bility for preventing and controlling TB. However, other health care pro-
viders who provide TB services also have responsibility for preventing and
controlling TB in their communities.  Prevention and control efforts should
include three priority strategies: (1) identifying and treating all persons
who have TB disease, (2) finding and evaluating persons who have been in
contact with TB patients to determine whether they have TB infection or
disease, and treating them appropriately, and (3) testing high-risk groups
for TB infection to identify candidates for treatment of latent infection and
to ensure the completion of treatment.
Objectives
After working through this chapter, you will be able to
• Describe the three priority strategies for preventing and controlling TB in
communities;
• Describe the activities health care providers offering direct services for TB patients
should conduct.
Preventing and Controlling TB
State and local health departments have the primary re-
sponsibility for preventing and controlling TB. However,
other health care providers who provide TB services in
settings such as private clinics, managed care organiza-
tions, HIV clinics, correctional facilities, and hospitals also
have responsibility for preventing and controlling TB in
communities.
Prevention and control efforts should be conducted through
the coordination of health care providers in a variety of
settings to ensure the provision of direct services for TB
patients. Prevention and control efforts should include
three priority strategies:
1. Identifying and treating all persons who have TB
disease. This means finding cases of TB and en-
suring that patients complete appropriate therapy;
2. Finding and evaluating persons who have been in contact with TB patients to deter-
mine whether they have TB infection or disease, and treating them appropriately;
Chapter Ten
Community TB Control
Preventing and Controlling TB
Three priority strategies:
➤ Identify and treat all persons with TB disease
➤ Identify contacts to persons with infectious TB;
evaluate and offer therapy
➤ Test high-risk groups for LTBI; offer therapy as
appropriate
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3. Testing high-risk groups for TB infection to identify candidates for treatment of
latent infection and to ensure the completion of treatment.
Health care providers offering direct services for TB pa-
tients should achieve the three priority strategies by work-
ing in cooperation with the local health department in the
following areas:
• Overall planning and policy development
• Identification of persons who have clinically ac-
tive TB
• Management of persons who have disease or
who are suspected of having disease
• Identification and management of persons in-
fected with M. tuberculosis
• Laboratory and diagnostic services
• Data collection and analysis
• Training and education
Overall Planning and Policy Development
TB control programs should develop an overall TB con-
trol strategy in collaboration with local clinicians, profes-
sional societies, and volunteer organizations. Ideally, the
plan should be developed by the state or local TB advi-
sory council, in conjunction with community TB coali-
tion representatives. This process includes periodic review
of applicable local laws, regulations, and policies that aim
to protect the public from TB to ensure that they are con-
sistent with currently recommended medical and public
health practices.
TB control programs should guide and oversee the TB
control efforts of local institutions and practitioners (and
local health departments where appropriate) to ensure that
these efforts reflect the current standards of care and public health practice.
Health department staff or other experts may provide consultation on patient care such as
treatment of drug-resistant TB, assessment of response to therapy, detection and manage-
ment of adverse drug reactions, methods of ensuring adherence to therapy such as the use of
directly observed therapy (DOT), laboratory methods, infection control practices, contact
or outbreak investigations, and access to available resources.
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Health care providers should work with health
department in the following areas:
➤ Overall planning and policy development
➤ Identification of persons with clinically active TB
➤ Management of persons with disease or TB
suspects
➤ Identification and management of persons with
LTBI
➤ Laboratory and diagnostic services
➤ Data collection and analysis
➤ Training and education
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Overall Planning and Policy
➤ Develop overall TB control strategy
➤ Review local laws, regulations, and policies
➤ Guide and oversee TB control efforts of local
institutions and practitioners
➤ Provide consultations in TB treatment, contact
investigations, and infection control practices
➤ Seek out necessary funding and resources
➤ Educate policymakers
105What the Clinician Should Know
TB control programs should seek the funding necessary for carrying out TB control activi-
ties, and they should educate policymakers about the local TB problem and local program
priorities, needs, and objectives. Programs should have adequate and appropriate staff to
meet their objectives.
Identification of Persons Who Have Clinically
Active TB
Although TB care and treatment are often provided by
other medical care providers, the health department has
the ultimate responsibility for ensuring that TB patients
do not transmit M. tuberculosis to others. Health depart-
ments must ensure that medical services are available,
accessible, and acceptable for TB patients, suspects, con-
tacts, and others at high risk, without regard to the pa-
tients’ ability to pay for such services.
Contact Investigation
Prompt and thorough contact investigation is essential for
the control of TB. The purpose of the investigation is to
find contacts who (1) have TB disease so that they can be given treatment, and further
transmission can be stopped, (2) have latent TB infection (LTBI) so they can be given treat-
ment, and (3) are at high risk of developing TB disease and therefore require treatment until
LTBI can be excluded.
The health department is legally responsible for ensuring that a complete and timely contact
investigation is done for the TB cases reported in its area. Therefore, health departments
should work closely with other agencies (e.g., managed care organizations, private provid-
ers) to ensure the prompt reporting of suspected TB cases. The health department should
work closely with other agencies to plan the contact investigation and receive a report of the
results. Occasionally, a contact investigation may be conducted by people outside of the
health department, but under the supervision of the health department.
Management of Persons Who Have Disease or
Who Are Suspected of Having Disease
TB programs should ensure that the services needed to
evaluate, treat, and monitor TB patients are readily avail-
able in each community. In some areas, the state health
department provides these services. In other areas, the lo-
cal health department or other medical providers (e.g.,
managed care organizations, private physicians) provide
treatment services to patients under the supervision of the
state TB control program. The management of persons
who have disease or who are suspected of having disease
involves a range of services which include
• Developing a treatment plan
Management of Persons Who Have
TB Disease or TB Suspects
Management involves range of services, which include
➤ Developing a treatment plan
➤ Promoting and ensuring adherence
➤ Providing a referral system for other medical problems
➤ Providing clinical consultation services
➤ Providing inpatient care when necessary
➤ Providing appropriate facilities to isolate and treat
patients with infectious TB
➤ Maintaining an infection control program
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Identification of Persons Who Have
Clinically Active TB
➤ Health department has ultimate responsibility for
ensuring TB patients do not transmit TB
Contact Investigation
Purpose of a contact investigation is to find persons who
➤ Have TB disease so treatment can be given, and further
transmission stopped
➤ Have LTBI so treatment can be given
➤ Are at high risk of developing TB disease and require
treatment until LTBI excluded
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• Promoting and ensuring adherence
• Providing a referral system for other medical problems
• Providing clinical consultation services
• Providing inpatient care when necessary
• Providing appropriate facilities to isolate and treat patients with infectious TB
• Maintaining an infection control program
Coordinating care with other health care providers and facilities is crucial to the prevention
and control of TB. TB patients often receive care in a variety of settings including HIV
clinics, managed care organizations, hospitals, correctional facilities, and nursing homes.
As patients move among these settings, continuity of care may be compromised unless a
system is in place to provide coordination of care.
Identification and Management of Persons Infected
with M. tuberculosis
TB control programs should establish working relation-
ships with other health care providers and agencies who
provide health care services to high-risk populations and
should assist them in developing and implementing test-
ing programs.
Testing for TB infection should be done in well-defined
groups. Groups that are not at high risk for TB should not
be tested routinely, because testing in low-risk popula-
tions diverts resources from other priority activities and
because positive tests in low-risk persons may not repre-
sent TB infection. Flexibility is needed in defining high-
priority groups for testing. The changing epidemiology
of TB indicates that the risk for TB among groups currently considered high priority may
decrease over time, and groups currently not identified as being at risk subsequently may be
considered as high priority.
Laboratory and Diagnostic Services
Both outpatient and inpatient facilities that offer services for TB patients should have ready
access to laboratory and diagnostic services. Access to radiological services includes radi-
ography equipment, trained radiography technicians, and radiograph interpretation by a
qualified person. Radiograph findings and reports should be available within 24 hours.
Identification and Management of
Persons with LTBI
➤ Establish working relationships with other health
care providers
➤ Target testing to well-defined high-risk groups
➤ Flexibility needed in defining high-priority groups
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Laboratory services should be readily accessible to pro-
vide results of acid-fast bacilli smear examinations within
24 hours of specimen collection. TB prevention and con-
trol programs should work closely with laboratories to
ensure the rapid delivery of specimens to the laboratory
and prompt reporting of acid-fast bacilli smear results,
culture results, and results of drug susceptibility tests to
the clinician and health department. Laboratory services
should also be available to provide monitoring of bacte-
riologic response to therapy.
Data Collection and Analysis
TB reporting is required by law in every state. All new
TB cases and suspected cases should be reported promptly
to the health department by the clinician. Cases may also
be reported by infection control nurses or by pharmacies
when TB drugs are dispensed. In addition, all positive
TB smears and cultures should be reported promptly by
laboratories.
Early reporting is important for the control of TB, and it
gives clinicians access to the resources of the health de-
partment for assistance in case management and contact
investigation. State and local health departments have dif-
ferent procedures for reporting TB and other infectious
diseases.  Health care providers should become familiar
with the system used in their area.
All drug susceptibility results should be forwarded to the
health department. These results are important for the
evaluation and treatment of infected contacts. In addition,
health departments use this information to determine drug
resistance rates and patterns in their area.
Training and Education
TB control programs should provide training for all pro-
gram staff and should provide leadership in TB education
to the community. TB control programs should form net-
works and coalitions with community-based organizations
that work in communities with a high prevalence of TB to
ensure that community leaders, clinicians, and
policymakers are knowledgeable about TB; to educate the
public about TB; and in some instances, to help provide
testing and prevention services.
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Laboratory and Diagnostic Services
➤ Readily accessible
➤ AFB results within 24 hours of specimen collection
➤ Clinicians promptly report all TB cases and
suspected cases
➤ All TB smear and culture results reported by
laboratories
Data Collection and Analysis
➤ TB reporting required in every state
➤ All new cases and suspected cases promptly
reported to health department




TB control programs should
➤ Provide training for program staff
➤ Provide leadership in TB education to the
community
➤ Ensure community leaders, clinicians, and
policymakers are knowledgeable about TB
➤ Educate the public
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Study Questions
Answers to these questions can be found in the text.
1. What are the three priority strategies for TB prevention and control efforts?
2. What activities should be conducted in TB prevention and control efforts?
3. What is a contact investigation, and why is it important in TB control efforts?
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Table 1.  Regimen Options for Treatment of Latent
TB Infection in HIV-Negative Persons
Regimens
Daily Twice Weekly†
Children Adults Children Adults
Duration Duration Duration Duration
     Isoniazid
  9 months  9 months  9 months 9 months
     Isoniazid
6 months 6 months
__________  ___________
    Rifampin
and Not  2 months Not  2 or 3 months
 recommended  recommended
Pyrazinamide
    Rifampin  4 months  4 months Not recommended
Drug
INH - isoniazid,  RIF - rifampin, RFB - rifabutin, PZA - pyrazinamide,  EMB - ethambutol
† Directly observed treatment of LTBI should be used.
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Minimum of 270 doses administered within 12 months
Twice-weekly regimens should consist of at least 76 doses administered
within 12 months.
Recommended regimen for pregnant women
Contraindicated for persons who have active hepatitis and end-stage liver
disease
Minimum of 180 doses administered within 9 months
Twice-weekly regimens should consist of at least 52 doses within 9 months.
Recommended regimen for pregnant women
6-month regimen not recommended for those with fibrotic lesions on chest
radiographs or children
Contraindicated for persons who have active hepatitis and end-stage
liver disease
Minimum of 60 doses to be administered within 3 months
Twice-weekly regimens should consist of at least 16 doses to be administered
 for 2 months or 24 doses to be administered for 3 months.
May be used for isoniazid-intolerant patients
Avoid PZA for pregnant women because of the risk of adverse effects to the fetus.
This regimen has not been evaluated in HIV- negative persons.
Contraindicated for persons who have active hepatitis and end-stage liver
disease
Minimum of 120 doses administered within 6 months
For persons who are contacts of patients with INH-resistant, RIF-susceptible
TB
May be used for patients who cannot tolerate INH or PZA
Comments
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Regimens
Daily Twice Weekly†
Children Adults Children Adults
Duration Duration Duration Duration
    INH 9 months 9 months 9 months 9 months
RIF




and Not 2 months Not 2-3 months
recommended recommended
PZA*
Table 2.  Regimen Options for Treatment of Latent
TB Infection for Persons with HIV Infection
Drug
INH - isoniazid;  PZA - pyrazinamide;  RFB - rifabutin;  RIF- rifampin; DOPT- directly observed preventive therapy; PIs -
protease inhibitors; NNRTIs - nonnucleoside reverse transcriptase inhibitors;
NRTIs - nucleoside reverse transcriptase inhibitors
*For patients with intolerance to PZA, some experts recommend the use of a rifamycin (RIF or RFB) alone for preventive
treatment.  Most experts agree that available data support the recommendation that this treatment can be administered for
as short a duration as 4 months, although some experts would treat for 6 months.
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Minimum of 270 doses administered History of an INH-induced reaction,
within 12 months including hepatic, skin or other allergic
reactions, or neuropathy
Twice-weekly regimens should consist
of at least 76 doses administered within Known exposure to person who has
12 months. INH-resistant TB
INH can be administered concurrently Chronic severe liver disease
with NRTIs, PIs, or NNRTIs
Directly observed treatment of latent TB
infection should be used when twice-
weekly dosing is used
Minimum of 60 doses to be administered History of a rifamycin-induced reaction,
within 3 months including hepatic, skin or other allergic
reactions, or thrombocytopenia
Twice-weekly regimens should consist of at
least 16 doses to be administered for 2 Pregnancy
months or 24 doses to be administered for
3 months. Chronic severe hyperuricemia
If RFB is administered, patient should be Chronic severe liver disease
monitored carefully for potential RFB drug
toxicity and potential decreased antiretroviral
drug activity.
Dose adjustments, alternative therapies, or
other precautions might be needed when
rifamycins are used (e.g., patients using
hormonal contraceptives must be advised
to use barrier methods, and patients using
methodone require dose adjustments).
PIs or NNRTIs should generally not be ad-
ministered concurrently with RIF; in this
situation, an alternative is the use of RFB†
and PZA.
Comments Contraindications
†The concurrent administration of rifabutin is contraindicated with hard-gel saquinavir and delavirdine.  An alternative is the
use of rifabutin with indinavir, nelfinavir, amprenavir, ritonavir, efavirenz, and possibly soft-gel saquinavir and nevirapine.
Caution is advised when using rifabutin with soft-gel saquinavir and nevirapine, because data regarding the use of rifabutin
with soft-gel saquinavir and nevirapine are limited.
Note: For patients whose organisms are resistant to 1 or more drugs, administer at least 2 drugs to which there is
demonstrated susceptibility and consult a TB medical expert. Clinicians should review the drug-susceptibility pattern of the
M. tuberculosis strain isolated from the infecting source-patient before choosing a preventive therapy regimen.
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INH – isoniazid,  RIF – rifampin,  PZA – pyrazinamide,  EMB – ethambutol,  SM – streptomycin
 
Note: For all patients, if susceptibility results show resistance to any of the first-line drugs or
if the patient remains symptomatic or smear or culture positive after 3 months, consult a
TB medical expert.
 








Drugs Interval and Duration
 
1 Pulmonary and 













Daily for 8 weeks
2 Pulmonary and 
























3 Pulmonary and 






















4 Smear- and culture-
negative pulmonary 











Follow option 1, 2, or 
3 for 8 weeks
5 Pulmonary and 
extrapulmonary TB in 
adults and children 









Daily for 4-8 weeks
 


















EMB or SM should be continued until 
susceptibility to INH and RIF is demonstrated.
In areas where primary INH resistance <4%, 
EMB or SM may not be necessary for patients 
with no individual risk factors for drug resistance.












Regimen should be directly observed.
After the 8 week induction phase, continue EMB 
or SM until susceptibility to INH and RIF is 
demonstrated, unless drug resistance is unlikely.
Regimen should be directly observed.





















 for 8 
weeks
Continue all four drugs for 4 months.
If drug resistance is unlikely (primary INH 
resistance <4% and patient has no individual risk 
factors for drug resistance), EMB or SM may not 














EMB or SM should be continued until 
susceptibility to INH and RIF is demonstrated.
In areas where primary INH resistance <4%, 
EMB or SM may not be necessary for patients 








For infants and children with miliary TB, bone and joint TB, or TB meningitis, treatment should last 
at least 12 months.  For adults with these forms of extrapulmonary TB, response to therapy should 










Avoid SM and PZA for pregnant women because of the risk of adverse effects to the fetus.
 
118 Core Curriculum on Tuberculosis
 






Induction Phase Continuation Phase





























Daily for 2 weeks 
and then 2 times/





Daily or 2 times/





















Daily for 2 weeks 
and then 2* times/
















































Daily for 2 weeks 

















Daily or  2–3 times/





Daily or 2–3 times/





3 times/week for 
4 months 
(18 weeks)
EMB – ethambutol,  INH – isoniazid,  PZA – pyrazinamide,  RFB  – rifabutin,  RIF – rifampin,  SM – streptomycin
PIs – protease inhibitors,  NNRTIs  – nonnucleoside reverse transcriptase inhibitors,  
NRTIs – nucleoside reverse transcriptase inhibitors
 





Concurrent administration of rifabutin is 
contraindicated with hard-gel saquinavir and  
delavirdine.
20%–25% increase in the dose of PIs or NNRTIs 
might be necessary
Patient should be monitored carefully for RFB 
drug toxicity (arthralgia, uveitis, leukopenia) if 
RFB is used concurrently with PIs or NNRTIs.
Evidence of decreased antiretroviral drug activity 
should be assessed periodically with HIV RNA 
levels.
No contraindication exists for the use of RFB with 
NRTIs.
If the patient is also taking nelfinavir, indinavir, amprenavir, 
or ritonavir, the daily dose of RFB is decreased from 300 
mg to 150 mg, and to 150 mg two or three times a week 
when used with ritonaivr.  The twice-weekly dose of RFB 
(300 mg) remains unchanged if the patient is also taking 
these PIs.
If the patient is also taking efavirenz, the daily dose of 
RFB is increased from 300 mg to 450 mg or 600 mg.
Thrice-weekly dosing for RFB has not been studied and 
cannot be currently recommended.
Can be used concurrently with antiretroviral 
regimens that include PIs, NRTIs, and  NNRTIs.
SM is contraindicated for pregnant women.
Every effort should be made to continue administering SM 
for the total duration of treatment.  When SM is not used for 
the recommended 9 months,  EMB should be added to the 
regimen and the treatment duration should be prolonged 
from 9 months (38 weeks) to 12 months (52 weeks).
Rifampin can be used for the treatment of active 
TB disease for patients whose antiretroviral 
regimen includes
• The NNRTI efavirenz and two nucleoside 
reverse transcriptase inhibitors (NRTIs);
• The protease inhibitor ritonavir and one or 
more NRTIs; or
• The combination of two protease inhibitors 
(ritonavir and either saquinavir hard-gel 
capsule of saquinavir soft-gel capsule).
NTRIs may be administered concurrently with RIF.
If appropriate, patients should be assessed every 
3 months to evaluate the decision to initiate 
antiretroviral therapy.
A 2–week “P-450 induction wash-out” period may 
be necessary between the last dose of RIF and 
the first dose of protease inhibitors or NNRTIs.
SM is contraindicated for pregnant women.
*  Duration of therapy should be prolonged for patients with delayed response to therapy.  Criteria for delayed response 


















 susceptibility to INH and RIF.
 
Note:  Directly observed therapy (DOT) is recommended for all TB treatment regimens.
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Daily 2 Times/Week* 3 Times/Week*


































































































































INH – isoniazid,  RIF – rifampin,  RFB – rifabutin,  PZA – pyrazinamide,  EMB – ethambutol,  
SM – streptomycin,  PIs – Protease Inhibitors,  NNRTIs – nonnucleoside reverse transcriptase inhibitors










Adjust weight-based dosages as weight changes.
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Drug interactions resulting in 
increased phenytoin (Dilantin) or 
disulfiram (Antabuse) levels
Baseline measurements of hepatic 
enzymes for adults
Repeat measurements if
• baseline results are abnormal
• patient is at high risk for adverse 
reactions
• patient has symptoms of adverse 
reactions






) may prevent 
peripheral neuropathy and CNS effects
10–15 mg/kg should be used for children 









Baseline measurements of CBC, platelets, 
and hepatic enzymes
Repeat measurements if
• baseline results are abnormal
• patient has symptoms of adverse 
reactions
Significant interactions with
methadone, birth control hormones, PIs, 
NNRTIs, and many other drugs
Contraindicated or should be used with 
caution when administered with PIs and 
NNRTIs
Colors body fluids orange










Baseline measurements of CBC, platelets, 
and hepatic enzymes
Repeat measurements if
• baseline results are abnormal
• patient has symptoms of adverse 
reactions





monitor for decreased antiretroviral activity 
and for RFB toxicity if RFB taken 
concurrently with PIs or NNRTIs
RFB is contraindicated in patients taking 
ritonavir or delavirdine
Reduces levels of many drugs 
(e.g., PIs, NNRTIs, methadone, dapsone, 
ketoconazole, hormonal contraceptives, 
etc.)
Colors body fluids orange








Baseline measurements of uric acid and 
hepatic enzymes
Repeat measurements if
• baseline results are abnormal
• patient has symptoms of adverse 
reactions
Treat hyperuricemia only if patient has 
symptoms




Baseline and monthly tests of visual acuity 
and color vision
Not recommended for children too young to 
be monitored for changes in vision unless 
TB is drug resistant
Optic neuritis may be unilateral, check 
each eye separately
Ototoxicity (hearing loss or 
vestibular dysfunction)
Renal toxicity
Baseline and repeat as needed of hearing 
and renal function tests
Ultrasound and warm compresses to 
injection site may reduce pain









The concurrent administration of rifabutin is contraindicated with hard-gel saquinavir and delavirdine.  An alternative is the use 
of rifabutin with indinavir, nelfinavir, amprenavir, ritonavir, efavirenz, and possibly soft-gel saquinavir and nevirapine.  Caution is 
advised when using rifabutin with soft-gel saquinavir and nevirapine, because data regarding the use of rifabutin with soft-gel 




If nelfinavir, indinavir, amprenavir, or ritonavir is administered with RFB, blood concentrations of the PIs decrease.  Thus, when 
RFB is used concurrently with any of these drugs, the daily dose of RFB  is reduced from 300 mg to 150 mg when used with 




If efavirenz is administered with RFB, blood concentrations of RFB decrease.  Thus, when RFB is used with efavirenz, the daily 




No maximum dosages for EMB but in obese patients dosage should be calculated on lean body weight.
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Severe abdominal pain and organ 
damage due to crystal deposition
 
PO–by mouth, IM–intramuscular,  IV–intravenous
 




Assess vestibular function and hearing function prior to 
initiation of therapy and at regular intervals during treatment
Measure blood urea nitrogen and creatinine throughout 
treatment
After bacteriologic conversion, dosage may be reduced 
to 2–3 times per week
Safety and effectiveness in children have not been 
established
Assess vestibular function and hearing function prior to 
initiation of therapy and at regular intervals during treatment
Measure blood urea nitrogen and creatinine throughout 
treatment
After bacteriologic conversion, dosage may be reduced 
to 2–3 times per week
Not approved by FDA for TB treatment
Assess vestibular function and hearing function prior to 
initiation of therapy and at regular intervals during treatment
Measure renal function and serum drug levels
After bacteriologic conversion, dosage may be reduced 
to 2–3 times per week
Not approved by FDA for TB treatment
Measure hepatic enzymes Start with low dosage and increase as tolerated




Start with low dosage and increase as tolerated
Monitor cardiac patients for sodium load
May cause hypothyroid condition, especially if used 
with ethionamide
Assess mental status
Measure serum drug levels
Start with low dosage and increase as tolerated
Pyridoxine may decrease CNS effects
Drug interactions Not approved by the FDA for TB treatment
Should not be used in children





Drug interactions Not approved by the FDA for TB treatment
Should not be used in children





Drug interactions Not approved by the FDA for TB treatment
Should not be used in children





Drug interactions Not approved by FDA for TB treatment
Avoid sunlight
Consider dosing at mealtime
Efficacy unproven
 
*  Consult product insert for detailed information




Doses for children the same as for adults.   Use these drugs only in consultation with a clinician experienced in the 
management of drug-resistant TB.
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Table 7. First-Line TB Drugs in Special Situations*
 
Drug CNS TB Disease Renal Insufficiency
 
Isoniazid Good penetration Normal clearance
Rifampin Fair penetration of inflamed 
meninges (10%–20%)
Normal clearance
Pyrazinamide Good penetration Clearance reduced
Decrease dose or prolong interval
Ethambutol Penetrates inflamed meninges 
(4%–64%)
Clearance reduced
Decrease dose or prolong interval
Streptomycin Fair penetration of inflamed 
meninges (20%)
Clearance reduced
Avoid in end-stage renal disease
 
CNS–central nervous system
*Consult product insert for detailed information.
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    Core Curriculum on Tuberculosis
Course #SS3043
Goal
The goal of this Core Curriculum on Tuberculosis: What the Clinician Should Know is to
provide the reader with basic information about TB. Upon completion of this educational
activity, the reader should possess a clear working knowledge of the diagnosis, treatment,
and prevention of TB infection and disease.
Accreditation
Continuing Medical Education (CME) Credit: The Centers for Disease Control and Pre-
vention (CDC) is accredited by the Accreditation Council for Continuing Medical Educa-
tion to provide continuing medical education for physicians. The CDC designates this edu-
cational activity for a maximum of 5 hours in category 1 credit towards the AMA Physician’s
Recognition Award. Each physician should claim only those hours of credit that he/she
actually spent in the educational activity.
Continuing Nursing Education (CNE) Credit: This activity for 6 contact hours is pro-
vided by CDC, which is accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Continuing Education Units (CEU): The CDC awards .5 Continuing Education Units
(CEUs). The CDC is an Authorized CEU Sponsor of the International Association for Con-
tinuing Education and Training.
Instructions
1. Read the Core Curriculum on Tuberculosis: What the Clinician Should Know, 4th ed.
2. Complete the posttest and evaluation. There are two options for completing the posttest
and evaluation to receive credit:
a. Mail: A continuing education packet (instructions, scan forms, and a postage-paid
return envelope) are included with the booklet. Complete the posttest and evalua-
tion and mail the packet to the CDC Continuing Education Program in the postage-
paid return envelope provided. You should receive certification of continuing edu-
cation credit in 4 to 6 weeks.
b. Internet: Go to www.cdc.gov/nchstp/tb/pubs/corecurr/ and follow the instruc-
tions for completing the posttest and evaluation on-line. You will receive immedi-
ate feedback and certification of continuing education credit.
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3. If you need additional continuing education packets, you may contact the CDC Con-
tinuing Education Program to request additional packets in one of the following ways:
a. Email: Send an email to www.CE@cdc.gov and provide your name, address, and
daytime phone number, and specify that you would like materials for the course
entitled Core Curriculum on Tuberculosis, course number SS3043.
b. Fax: Place a toll-free call from a touch tone phone to 888-CDC-FAXX (888-232-
3299). When prompted, enter document number 564007, then enter your 10-digit
fax number. Fax the completed continuing education request form to 404-639-0800.
c. Phone: Call 1-800-41-TRAIN, follow the prompts, and state your request for a
continuing education packet for the course entitled Core Curriculum on Tuberculosis,
course number SS3043.
You should receive your continuing education packet in 2 to 3 weeks.




Answer A = True or B = False
1. TB is spread from person to person through the air.
A. True
B. False
2. Secondary drug resistance develops during TB therapy.
A. True
B. False




4. The Mantoux tuberculin skin test is given by using a needle and syringe to inject 0.1 ml




5. The use of anergy testing in conjunction with tuberculin skin testing is routinely recom-
mended for screening programs for M. tuberculosis infection conducted among HIV-
positive persons in the United States.
A. True
B. False
6. Culture examinations should be done on all specimens regardless of AFB smear results.
A. True
B. False
7. A rifampin-based TB treatment regimen is recommended for HIV-positive patients who
have started on antiretroviral therapy.
A. True
B. False
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8. The best way to measure the effectiveness of treatment is to obtain specimens for
culture at least monthly.
A. True
B. False
9. In isolation rooms, ventilation systems are necessary to maintain positive pressure
and exhaust the air properly.
A. True
B. False
10. Personal respirators should be used in settings where administrative and engineering
controls may not fully protect health care workers from infectious droplet nuclei.
A. True
B. False








For questions 13 - 20, answer true or false for the conditions that can increase the risk that
TB infection will progress to TB disease.
13. High blood pressure
14. Injection of illicit drugs
15. HIV infection
16. Normal chest x-ray
17. Diabetes mellitus
18. Silicosis
19. High body weight (20% or more above the ideal)
20. Recent TB infection (within the past 2 years)
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Multiple Choice
Choose the one best answer.
21. Which of the following statements is true?
A. During 1992-1998, the overall decrease in TB cases reflected the substantial
decline in cases among U.S.-born persons in all age groups and a small increase
in the number of cases among foreign-born persons
B. During 1992-1998, the overall decrease in TB cases reflected the substantial
increase in cases among U.S.-born persons in all age groups and a small decrease
in the number of cases among foreign-born persons
C. During 1992-1998, the overall decrease in TB cases reflected the substantial
decline in cases among U.S.-born persons in all age groups and a small decrease
in the number of cases among foreign-born persons
D. During 1992-1998, the overall decrease in TB cases reflected the substantial
increase in cases among U.S.-born persons in all age groups and a small increase
in the number of cases among foreign-born persons
22. Generally, what percentage of people in the United States who have TB infection and





23. For the following groups, what induration size is considered a positive reaction?
(Choose only one answer for all 3 groups)
• Recent contacts of a TB case
• HIV-positive persons
• People who have chest x-ray findings consistent with old healed TB
A. 5 millimeters or greater
B. 10 millimeters or greater
C. 15 millimeters or greater
132 Core Curriculum on Tuberculosis
24. Which of the following groups should be given high priority for treatment of latent TB?
A. Patients with organ transplants and other immunosuppressed patients
B. HIV-positive persons
C. Recent contacts of a TB case
D. Persons with fibrotic changes consistent with old healed TB
E. All of the above
25. Which of the following regimens is an alternative to isoniazid for treatment of LTBI
in HIV-positive persons?
A. Streptomycin and ethambutol
B. Rifampin and pyrazinamide
C. Ethambutol and pyrazinamide
D. Rifampin and ethambutol
26. Which of the following treatment-of-latent-TB-infection regimens is an alternative to
isoniazid for HIV-positive persons who are receiving protease inhibitors or
nonnucleoside reverse transcriptase inhibitors?
A. Streptomycin and ethambutol
B. Rifampin and pyrazinamide
C. Ethambutol and pyrazinamide
D. Rifabutin and pyrazinamide
27. How often should patients be evaluated for signs and symptoms of active TB disease
during treatment of LTBI?
A. Weekly
B. At least monthly
C. Only if symptoms of adverse reactions occur
D. Every 3 months
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28. The recommended regimen for the initial phase of a 6-month regimen for TB in HIV-
negative individuals is
A. Isoniazid and rifampin
B. Isoniazid, rifampin, pyrazinamide, and ethambutol or streptomycin
C. Isoniazid, rifabutin, ethambutol
D. Isoniazid, rifabutin, streptomycin, ethionamide
29. Which of the following is recommended as the initial phase of a 6-month TB regimen
for HIV-positive patients who are on or will begin an antiretroviral regimen including
protease inhibitors or nonnucleoside reverse transcriptase inhibitors?
A. Isoniazid, rifampin, pyrazinamide, ethambutol
B. Isoniazid, ethambutol, pyrazinamide, streptomycin
C. Isoniazid, rifabutin, pyrazinamide, ethambutol
D. Isoniazid, rifampin, pyrazinamide, ethionamide
30. Which of the following describes directly observed therapy (DOT)?
A. A public health worker gives the patient a bottle of pills monthly.
B. A designated individual watches the patient swallow every dose of the prescribed
medication.
C. A public health worker counts the remaining pills in the medication bottles.
D. All of the above





134 Core Curriculum on Tuberculosis
32. When can a TB patient be considered noninfectious?
A. When they are on adequate therapy
B. When they have had a significant clinical response to therapy
C. When they have had 3 consecutive negative sputum smear results from specimens
collected on different days
D. When all of the above are true
33. What are the three types of controls in an infection control program?
A. Administrative, isolation, personal respiratory protection
B. Administrative, engineering, personal respiratory protection
C. Isolation, ventilation systems, HEPA filtration
D. Ventilation systems, personal respiratory protection, HEPA filters
34. A diagnosis of M. tuberculosis infection and the use of treatment for infection should
be considered for a BCG-vaccinated person with a reaction of ≥10 mm of induration if
A. The vaccinated person is a contact of another person who has infectious TB
B. The vaccinated person was born or has resided in a country in which the prevalence
of TB is high
C. The vaccinated person is exposed continually to populations in which the preva-
lence of TB is high
D. All of the above
35. BCG vaccination should be considered in which of the following circumstances:
A. A child who is continually exposed to a patient who had noninfectious pulmonary
TB caused by M. tuberculosis strains resistant to isoniazid and rifampin and the
child can be separated from the presence of the noninfectious patient
B. A child who is continually exposed to an untreated or ineffectively treated patient
who has infectious pulmonary TB and the child cannot be separated from the
presence of the infectious patient
C. Health care workers who work in settings where there is a high percentage of TB
patients infected with M. tuberculosis
D. All of the above
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Multiple - Multiples
For each question there are 4 choices listed (1, 2, 3, and 4). Choose the best
answer (A, B, C, D, or E) which consists of multiple combinations of correct
answers.
A = 1, 2, and 3 are correct
B = 1 and 3 are correct
C = 2 and 4 are correct
D = Only 4 is correct
E = All are correct
36. Which of the following statements is correct?
1. All persons with class 3 or class 5 TB should be reported promptly to the health
department.
2. A patient should not have a class 5 classification for more than 3 months.
3. The current clinical classification system for TB is based on the pathogenesis of
the disease.
4. Health care providers should comply with state and local laws and regulations
requiring the reporting of TB.
37. Which of the following is true about two-step testing?
1. Two-step testing should be used for the initial skin testing of adults who will be
retested periodically.
2. Two-step testing is used to reduce the likelihood that a boosted reaction will be
misinterpreted as a recent infection.
3. Delayed-type hypersensitivity to tuberculin may wane over the years and a skin
test may boost the ability to react to tuberculin, causing a positive reaction to
subsequent tests.
4. Two-step testing should be used for all adults.
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39. Which of the following confirms the diagnosis of TB?
1. Chest x-ray
2. Detection of acid-fast bacilli in smear examination
3. Positive tuberculin skin test
4. Positive culture of M. tuberculosis
40. Which of the following persons are at an increased risk for drug resistance?
1. Contacts of persons known to have drug-resistant TB
2. Persons receiving inadequate TB treatment regimens for >2 weeks
3. Persons whose smears or cultures remain positive despite 2 months of therapy
with TB drugs
4. Persons who have a history of treatment with TB drugs
41. Which of the following are priorities for state and local health departments?
1. Identifying and treating all persons who have TB disease
2. Finding and evaluating persons who have been in contact with TB patients to deter-
mine whether they have TB infection or disease and treating them appropriately
3. Testing high-risk groups for TB infection to identify candidates for treatment of
latent infection and to ensure the completion of therapy
4. Testing all groups for TB infection to identify candidates for treatment of latent
infection and to ensure the completion of therapy
42. Which of the following are roles of the health department?
1. Conducting contact investigations
2. Ensuring that TB patients do not transmit M. tuberculosis to others
3. Periodically reviewing applicable local laws, regulations, and policies that aim to
protect the public from TB
4. Conducting surveillance of all new cases and suspected cases
A = 1, 2, and 3 are correct
B = 1 and 3 are correct
C = 2 and 4 are correct
D = Only 4 is correct
E = All are correct
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Evaluation Questions
Multiple Choice
43. I am applying for (choose only one):
A. Continuing medical education (CME) credit
B. Continuing nursing education (CNE) credit
C. Continuing education units (CEU)




D. Respiratory Care Practitioner
E. Student
F. Other
45. Please indicate the setting where you work:
A. City/county/state health department
B. Other public health agency (e.g., drug treatment facility, Federal agency, nursing
home, correctional institution, community based organization)
C. Hospital
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46. Indicate the approximate percentage of time that you spend on your job working on TB
activities:
A. 75% - 100%
B. 50% - 74%
C. 25% - 49%
D. 10% - 24%
E. 1% - 9%
F. 0%
47. Approximately how long did it take you to read the publication and complete the exam?
A. Less than 5 hours
B. 5-7 hours
C. 8-9 hours
D. Greater than 9 hours
48. How did you learn about this continuing education activity?
A. Internet (World Wide Web)
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The following questions will assess your perceptions of the readability and applicability
of the material.
Strongly Agree Neither Disagree Strongly
agree agree nor disagree
disagree
49. The objectives of this A B C D E
course were clearly stated
and achieved.




51. The course materials were A B C D E
organized, clear, and
helpful.
52. I will use this publication A B C D E
as a teaching tool.
53. Overall, the objectives met A B C D E
the stated goals of this
publication.
